Document:

Exhibit 10.2

 

EDGEWISE THERAPEUTICS, INC.

 

2017 EQUITY INCENTIVE PLAN

 

As Adopted by the Board and Stockholders
on June 5, 2017

Amended by the Board and Stockholders
as of November 30, 2020

 

1.             PURPOSE.
The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential
contributions are important to the success of the Company, its Parent and Subsidiaries, by offering them an opportunity to participate
in the Company’s future performance through Awards. Capitalized terms not defined in the text are defined in Section 23.
Awards may be either Restricted Stock or Options. Options granted under the Plan may be ISOs (as defined in Section 5 hereof)
or NQSOs (as defined in Section 5 hereof), as determined by the Committee at the time of grant of an Option and subject to
the applicable provisions of Section 422 of the Code and the regulations promulgated thereunder. This Plan is intended to
be a written compensatory benefit plan within the meaning of Rule 701 promulgated under the Securities Act.

 

2.             SHARES
SUBJECT TO THE PLAN.

 

2.1.          Number
of Shares Available. Subject to Sections 2.2 and 16, the total number of Shares reserved
and available for grant and issuance pursuant to this Plan will be 12,585,602 Shares or such lesser number of Shares as permitted
under Section 260.140.45 of Title 10 of the California Code of Regulations. Subject to Sections 2.2, 5.10 and 16, Shares
subject to Awards previously granted will again be available for grant and issuance in connection with future Awards under this
Plan to the extent such Shares: (i) cease to be subject to issuance upon exercise of an Option, other than due to the exercise
of such Option; or (ii) are issued upon exercise of an Award but are forfeited or repurchased by the Company. At all times
the Company will reserve and keep available a sufficient number of Shares as will be required to satisfy the requirements of all
Awards granted and outstanding under this Plan. Notwithstanding the foregoing, in no event shall the total number of Shares issued
(counting each reissuance of a Share that was actually issued and then forfeited or repurchased by the Company as a separate issuance)
under the Plan upon exercise of ISOs exceed 10,000,000 Shares (adjusted in accordance with Sections 2.2 and 16 hereof) over the
term of the Plan.

 

2.2.          Adjustment
of Shares. In the event that the number of outstanding shares of the Company’s
Common Stock is changed by a stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification
or similar change in the capital structure of the Company without consideration, consolidation, subdivision of the Shares, a rights
offering, a reorganization, merger, spin-off, or split-up, then (i) the number of Shares reserved for issuance under this
Plan; (ii) the Exercise Prices of and number of Shares subject to outstanding Options and (iii) any repurchase price
per Share applicable to Shares issued pursuant to any Award, will be proportionately adjusted, subject to any required action
by the Board or the stockholders of the Company and compliance with applicable securities laws; provided, however, that fractions
of a Share will not be issued but will either be paid in cash at the Fair Market Value of such fraction of a Share or will be
rounded down to the nearest whole Share, as determined by the Committee and provided, further, that the Exercise Price of any
Option may not be decreased to below the par value of the Shares.

 

    

     

    

 

3.             ELIGIBILITY.
ISOs may be granted only to employees (including officers and directors who are also employees) of the Company or of a Parent
or Subsidiary of the Company. Restricted Stock or NQSO’s may be granted to employees, officers, directors and consultants
of the Company or any Parent or Subsidiary of the Company. Consultants need not be individuals provided that the issuances to
such consultant is in compliance with all Applicable Laws. A person may be granted more than one Award under this Plan.

 

4.             ADMINISTRATION.

 

4.1.          Committee
Authority. This Plan will be administered by the Board, though the Board may appoint
a Committee to which it delegates such administration. If the Board has not appointed a Committee to administer the Plan, the
Board itself shall serve as the Committee. The Plan may be administered by different administrative bodies with respect to different
classes of Participants. Subject to the general purposes, terms and conditions of this Plan, and to the direction of the Board,
the Committee will have full power to implement and carry out this Plan. Without limitation, the Committee will have the authority
to:

 

4.1.1.          determine
the Fair Market Value of the Common Stock;

 

4.1.2.          construe
and interpret this Plan, any Option Agreement (as defined in Section 5.1 hereof) or Restricted Stock Purchase Agreement and
any other agreement or document executed pursuant to this Plan, which constructions, interpretations and decisions shall be final
and binding on all Participants;

 

4.1.3.          prescribe,
amend and rescind rules and regulations relating to this Plan;

 

4.1.4.          approve
persons to receive Awards;

 

4.1.5.          determine
the number of Shares or other consideration subject to Awards;

 

4.1.6.          determine
whether Awards will be granted singly, in combination with, in tandem with, in replacement of, or as alternatives to, other Awards
under this Plan or awards under any other incentive or compensation plan of the Company or any Parent or Subsidiary of the Company;

 

4.1.7.          grant
waivers of any conditions of this Plan or any Award;

 

4.1.8.          determine
the form and terms, not inconsistent with the terms of the Plan, of any Awards granted hereunder and other related documents used
under the Plan, which terms and conditions include but are not limited to the exercise or purchase price, the time or times when
Awards may be exercised (which may be based on performance criteria), the circumstances (if any) when vesting will be accelerated
or forfeiture restrictions will be waived, and any restriction or limitation regarding, any Award;

 

    2

     

    

 

4.1.9.          correct
any defect, supply any omission, or reconcile any inconsistency in this Plan, any Award, any Option Agreement, any Exercise Agreement,
or any Restricted Stock Purchase Agreement;

 

4.1.10.          determine
whether an Award has been earned;

 

4.1.11.          determine
whether and under what circumstances an Award may be settled in cash under Section 13 below instead of Common Stock;

 

4.1.12.          implement
an Option Exchange Program and establish the terms and conditions of such Option Exchange Program, provided that no amendment
or adjustment to an Option that would materially and adversely affect the rights of any Participant shall be made without his
or her consent;

 

4.1.13.          make
all other determinations necessary or advisable for the administration of this Plan; and

 

4.1.14.          extend
the vesting period beyond a Participant’s Termination Date.

 

4.2.          Committee
Discretion. Unless in contravention of any express terms of this Plan or any Award,
any determination made by the Committee with respect to any Award will be made in its sole discretion either (i) at the time
of grant of the Award, or (ii) subject to Section 5.9 hereof, at any later time. Any such determination will be final
and binding on the Company and on all persons having an interest in any Award under this Plan. The Committee may delegate to one
or more officers of the Company the authority to grant Awards under this Plan, provided such officer or officers are members of
the Board.

 

4.3.          Indemnification.
To the maximum extent permitted by Applicable Laws, each member of the Committee (including officers of the Company, if applicable),
or of the Board, as applicable, shall be indemnified and held harmless by the Company against and from (i) any loss, cost,
liability, or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim,
action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken
or failure to act under the Plan or pursuant to the terms and conditions of any Award except for actions taken in bad faith or
failures to act in good faith, and (ii) any and all amounts paid by him or her in settlement thereof, with the Company’s
approval, or paid by him or her in satisfaction of any judgment in any such claim, action, suit, or proceeding against him or
her, provided that such member shall give the Company an opportunity, at its own expense, to handle and defend any such claim,
action, suit, or proceeding before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right
of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the
Company’s Articles of Incorporation, Certificate of Incorporation or Bylaws, by contract, matter of law, or otherwise, or
under any other power that the Company may have to indemnify or hold harmless each such person.

 

    3

     

    

 

5.             OPTIONS.
The Committee may grant Options to eligible persons described in Section 3 hereof and will determine whether such Options
will be Incentive Stock Options within the meaning of the Code (the “ISOs”) or Nonqualified Stock Options
(the “NQSOs”), the number of Shares subject to the Option, the Exercise Price of the Option, the period
during which the Option may be exercised, and all other terms and conditions of the Option, subject to the following:

 

5.1.          Form of
Option Grant. Each Option granted under this Plan will be evidenced by an Option
Agreement which will expressly identify the Option as an ISO or an NQSO, and will be in such form and contain such provisions
(which need not be the same for each Participant) as the Committee may from time to time approve, and which will comply with and
be subject to the terms and conditions of this Plan.

 

5.2.          Date
of Grant. The date of grant of an Option will be the date on which the Committee
makes the determination to grant such Option, unless a later date is otherwise specified by the Committee. The Option Agreement
and a copy of this Plan will be delivered to the Participant within a reasonable time after the granting of the Option.

 

5.3.          Exercise
Period. Options may be exercisable immediately but shares so exercised prior to becoming
Vested Shares shall be subject to repurchase pursuant to Section 5.12 hereof or may be exercisable within the times or upon
the events determined by the Committee as set forth in the Option Agreement governing such Option; provided, however, that no
Option will be exercisable after the expiration of ten (10) years from the date the Option is granted; and provided further
that no ISO granted to a person who immediately prior to the grant of such ISO directly or by attribution owns more than ten percent
(10%) of the total combined voting power of all classes of stock of the Company or of any Parent or Subsidiary of the Company
(the “Ten Percent Stockholder”) will be exercisable after the expiration of five (5) years from
the date the ISO is granted. The Committee also may provide for Options to become exercisable at one time or from time to time,
periodically or otherwise, in such number of Shares or percentage of Shares as the Committee determines.

 

5.4.          Exercise
Price. The Exercise Price of an Option will be determined by the Committee when the
Option is granted; provided that (i) the Exercise Price of an ISO will not be less than one hundred percent (100%) of the
Fair Market Value of the Shares on the date of grant and (ii) the Exercise Price of any Option granted to a Ten Percent Stockholder
will not be less than one hundred ten percent (110%) of the Fair Market Value of the Shares on the date of grant. In the case
of an NQSO, the per share exercise price shall be such price that is determined by the Committee, provided that, if the per Share
exercise price is less than 100% of the Fair Market Value on the date of grant, it shall otherwise comply with all Applicable
Laws, including Section 409A of the Code. Payment for the Shares purchased must be made in accordance with Section 7
hereof.

 

    4

     

    

 

5.5.          Method
of Exercise. Options may be exercised only by delivery to the Company of a written
stock option exercise agreement (the “Exercise Agreement”) in a form approved by the Committee (which
need not be the same for each Participant). The Exercise Agreement will state (i) the number of Shares being purchased, (ii) such
representations and agreements regarding Participant’s investment intent and access to information and other matters, if
any, as may be required or desirable by the Company to comply with applicable securities laws, and (iii) any repurchase terms
attributable to unvested Shares that have been exercised. Participant shall execute and deliver to the Company the Exercise Agreement
together with payment in full of the Exercise Price, and any applicable taxes, for the number of Shares being purchased. Options
may not be exercised for a fraction of a share.

 

5.6.          Termination.
Subject to earlier termination pursuant to Sections 16 or 17 hereof and notwithstanding the exercise periods set forth in the
Option Agreement, exercise of an Option will always be subject to the following:

 

5.6.1.          If
the Participant (or other person entitled to exercise the Option) does not exercise the Option to the extent so entitled within
the time specified below, the Option shall terminate and the Shares underlying the unexercised portion of the Option shall revert
to the Plan. In no event may any Option be exercised after the expiration of the Option term as set forth in the Option Agreement
(and subject to Section 5.3 above).

 

5.6.2.          If
the Participant is Terminated for any reason other than death, Disability or for Cause, then the Participant may exercise such
Participant’s Options only to the extent that such Options are exercisable upon the Termination Date or as otherwise determined
by the Committee. Such Options must be exercised by the Participant, if at all, as to all or some of the Vested Shares calculated
as of the Termination Date or such other date determined by the Committee, within ninety (90) days after the Termination Date
(or within such shorter time period, not less than thirty (30) days, or within such longer time period, not exceeding five (5) years
after the Termination Date as may be determined by the Committee, with any exercise beyond ninety (90) days after the Termination
Date deemed to be an NQSO) but in any event, no later than the expiration date of the Options.

 

5.6.3.          If
the Participant is Terminated because of Participant’s death or Disability (or the Participant dies within ninety (90) days
after a Participant’s Termination other than for Cause), then Participant’s Options may be exercised, only to the
extent that such Options are exercisable by Participant on the Termination Date or as otherwise determined by the Committee. Such
Options must be exercised by Participant (or Participant’s legal representative or authorized assignee), if at all, as to
all or some of the Vested Shares calculated as of the Termination Date or such other date determined by the Committee, within
twelve (12) months after the Termination Date (or within such shorter time period, not less than six (6) months, or within
such longer time period not exceeding five (5) years after the Termination Date as may be determined by the Committee, with
any exercise beyond (i) ninety (90) days after the Termination Date when the Termination is for any reason other than the
Participant’s death or Disability, or (ii) twelve (12) months after the Termination Date when the Termination is for
Participant’s Disability, deemed to be an NQSO) but in any event no later than the expiration date of the Options.

 

    5

     

    

 

5.6.4.          The
Committee shall have the discretion to determine whether and to what extent the vesting of Options shall be tolled during any
unpaid leave of absence; provided, however, in the absence of such determination, such vesting shall be tolled during any such
unpaid leave (unless otherwise required by Applicable Laws). Notwithstanding the foregoing, in the event of military leave, vesting
shall toll during any unpaid portion of such leave, provided that, upon a Participant’s returning from military leave (under
conditions that would entitle him or her to protection upon such return under the Uniform Services Employment and Reemployment
Rights Act), he or she shall be given vesting credit with respect to Options to the same extent as would have applied had the
Participant continued to provide services to the Company (or any Parent or Subsidiary, if applicable) throughout the leave on
the same terms as he or she was providing services immediately prior to such leave.

 

5.7.          Limitations
on Exercise. The Committee may specify a reasonable minimum number of Shares that
may be purchased on any exercise of an Option, provided that such minimum number will not prevent Participant from exercising
the Option for the full number of Shares for which it is then exercisable.

 

5.8.          Limitations
on ISOs. The aggregate Fair Market Value (determined as of the date of grant)
of Shares with respect to which ISOs are exercisable for the first time by a Participant during any calendar year (under this
Plan or under any other incentive stock option plan of the Company or any Parent or Subsidiary of the Company) will not exceed
One Hundred Thousand Dollars ($100,000). If the Fair Market Value of Shares on the date of grant with respect to which ISOs are
exercisable for the first time by a Participant during any calendar year exceeds One Hundred Thousand Dollars ($100,000), then
the Options for the first One Hundred Thousand Dollars ($100,000) worth of Shares to become exercisable in such calendar year
will be ISOs and the Options for the amount in excess of One Hundred Thousand Dollars ($100,000) that become exercisable in that
calendar year will be NQSOs. In the event that the Code or the regulations promulgated thereunder are amended after the Effective
Date (as defined in Section 17 hereof) to provide for a different limit on the Fair Market Value of Shares permitted to be
subject to ISOs, then such different limit will be automatically incorporated herein and will apply to any Options granted after
the effective date of such amendment. For purposes of this Section 5.8, ISOs shall be taken into account in the order
in which they were granted, and the Fair Market Value of the Shares subject to an ISO shall be determined as of the date of the
grant of such Option.

 

5.9.          Modification,
Extension or Renewal. The Committee may modify, extend or renew outstanding Options
and authorize the grant of new Options in substitution therefor, provided that any such action may not, without the written consent
of a Participant, impair any of such Participant’s rights under any Option previously granted. Any outstanding ISO that
is modified, extended, renewed or otherwise altered will be treated in accordance with Section 424(h) of the Code. Subject
to Section 5.10 hereof, the Committee may reduce the Exercise Price of outstanding Options without the consent of Participants
by a written notice to them; provided, however, that the Exercise Price may not be reduced below the minimum Exercise Price that
would be permitted under Section 5.4 hereof for Options granted on the date the action is taken to reduce the Exercise Price;
provided, further, that the Exercise Price will not be reduced below the par value of the Shares, if any.

 

    6

     

    

 

5.10.          No
Disqualification. Notwithstanding any other provision in this Plan, no term of this
Plan relating to ISOs will be interpreted, amended or altered, nor will any discretion or authority granted under this Plan be
exercised, so as to disqualify this Plan under Section 422 of the Code or, without the consent of the Participant, to disqualify
any Participant’s ISO under Section 422 of the Code.

 

5.11.          Right
of First Refusal. At the discretion of the Committee, the Company may reserve to
itself and/or its assignee(s) in the Option Agreement a right of first refusal to purchase all Shares that a Participant
(or a subsequent transferee) may propose to transfer to a third party, unless otherwise not permitted by Section 25102(o) of
the California Corporations Code, including a right of purchase upon an involuntary transfer; provided, that such right of first
refusal terminates upon the Company’s initial public offering of Common Stock pursuant to an effective registration statement
filed under the Securities Act.

 

5.12.          Early
Exercise. Any Option may, but need not, include a provision whereby the Participant
may elect at any time before the Termination of such Participant to exercise the Option as to any part or all of the Shares subject
to the Option prior to the full vesting of such Shares. Any Unvested Shares so purchased shall be subject to a repurchase option
in favor of the Company or to any other restriction the Committee determines to be appropriate.

 

6.             RESTRICTED
STOCK

 

6.1.          Rights
to Purchase. When a right to purchase Restricted Stock is granted under the Plan,
the Committee shall advise the recipient in writing of the terms, conditions and restrictions related to the offer, including
the number of Shares that such person shall be entitled to purchase, the Purchase Price (which shall be determined by the Committee,
subject to Applicable Laws, including any applicable securities laws), and the time within which such person must accept such
offer. The permissible consideration for Restricted Stock shall be determined by the Committee and shall be made in accordance
with Section 7 below. The offer to purchase Shares shall be accepted by execution of a Restricted Stock Purchase Agreement
in a form determined by the Committee.

 

6.2.          Repurchase
Option

 

6.2.1.          General.
Unless the Committee determines otherwise, the Restricted Stock Purchase Agreement shall grant the Company a repurchase option
exercisable if the Participant is Terminated for any reason (including death or Disability). The purchase price for the Shares
repurchased pursuant to the Restricted Stock Purchase Agreement shall be equal to or less than the Purchase Price paid by the
Participant and may be paid by cancellation of any indebtedness of the Participant to the Company. The repurchase option shall
lapse at such rate as the Committee shall determine.

 

    7

     

    

 

6.2.2.          Leave
of Absence. The Committee shall have the discretion to determine whether and to what
extent the lapsing of the Company’s repurchase rights shall be tolled during any unpaid leave of absence; provided, however,
in the absence of such determination, such lapsing shall be tolled during any such unpaid leave (unless otherwise required by
Applicable Laws). Notwithstanding the foregoing, in the event of military leave, the lapsing of the Company’s repurchase
rights shall toll during any unpaid portion of such leave, provided that, upon a Participant’s returning from military leave
(under conditions that would entitle him or her to protection upon such return under the Uniform Services Employment and Reemployment
Rights Act), he or she shall be given vesting credit with respect to Shares purchased pursuant to the Restricted Stock Purchase
Agreement to the same extent as would have applied had the Participant continued to provide services to the Company (or any Parent
or Subsidiary, if applicable) throughout the leave on the same terms as he or she was providing services immediately prior to
such leave.

 

6.2.3.          The
Participant shall have full stockholder rights with respect to any Shares issued to the Participant under a Restricted Stock Award,
whether or not the Participant’s interest in those Shares is vested. Accordingly, the Participant shall have the right to
vote such shares and to receive any regular cash dividends paid on such shares.

 

6.2.4.          Any
new, substituted or additional securities or other property (including money paid other than as a regular cash dividend) which
the Participant may have the right to receive with respect to the Participant’s Unvested Shares by reason of any stock split,
reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, exchange of shares or
other change affecting the outstanding Common Stock as a class without the Company’s receipt of consideration shall be issued
subject to (i) the same vesting requirements applicable to the Participant’s Unvested Shares and (ii) such escrow
arrangements as the Committee shall deem appropriate.

 

6.3          Right
of First Refusal. At the discretion of the Committee, the Company may reserve to
itself and/or its assignee(s) in the Restricted Stock Purchase Agreement a right of first refusal to purchase all Shares
that a Participant (or a subsequent transferee) may propose to transfer to a third party, unless otherwise not permitted by Section 25102(o) of
the California Corporations Code, including a right of purchase upon an involuntary transfer; provided, that such right of first
refusal terminates upon the Company’s initial public offering of Common Stock pursuant to an effective registration statement
filed under the Securities Act.

 

7.             PAYMENT
FOR SHARE PURCHASES.

 

7.1.          Payment.
Payment for Shares purchased pursuant to this Plan whether by exercise of an Option or purchase under Restricted Stock Purchase
Agreement shall be made in cash (by check or wire transfer); provided, however, that where expressly provided in an Option Agreement
or Restricted Stock Purchase Agreement or otherwise approved for the Participant by the Committee, and where permitted by Applicable
Law, payment may be made by one or more of the following methods:

 

7.1.1.          by
cancellation of indebtedness of the Company owed to the Participant;

 

    8

     

    

 

7.1.2.          for
past services rendered to the Company, unless prohibited by Applicable Law;

 

7.1.3.          by
surrendering, or attesting to the ownership of, shares of Common Stock that are already owned by the Participant, provided such
shares shall be surrendered to the Company in good form for transfer, clear of all liens, claims, encumbrances or security interests,
and shall be valued at their Fair Market Value as of the date of exercise or purchase;

 

7.1.4.          by
tender of a promissory note having such recourse, interest, security and redemption provisions as the Committee determines, bearing
interest at a rate sufficient to avoid imputation of income under Sections 483 and 1274 of the Code; provided, however, that the
portion of the Exercise Price or Purchase Price, as applicable, equal to the par value of the Shares must be paid in cash or other
legal consideration permitted by Applicable Law;

 

7.1.5.          provided
that a public market for the Common Stock exists, by the delivery (on a form prescribed by the Company) of an irrevocable direction
to a securities broker approved by the Company to sell Shares and to deliver all or part of the sales proceeds to the Company;

 

7.1.6.          by
a “net exercise” arrangement pursuant to which the Company will reduce the number of Shares issued upon exercise of
an Option by the largest whole number of Shares having an aggregate Fair Market Value that does not exceed the aggregate Exercise
Price or the sum of the aggregate Exercise Price plus all or a portion of the minimum amount required to be withheld under applicable
tax law (with the Company accepting from the Optionee payment of cash or cash equivalents to satisfy any remaining balance of
the aggregate Exercise Price and, if applicable, any additional withholding obligation not satisfied through such reduction in
Shares); provided that to the extent Shares subject to an Option are withheld in this manner, the number of Shares subject
to the Option following the net exercise will be reduced by the sum of the number of Shares withheld and the number of Shares
delivered to the Optionee as a result of the exercise;

 

7.1.7.          by
any other form permitted by Applicable Law; and

 

7.1.8.          by
any combination of the foregoing.

 

7.2.          Loan
Guarantees. The Committee may, in its sole discretion, elect to assist the Participant
in paying for Shares purchased under this Plan by authorizing a guarantee by the Company of a third-party loan to the Participant.

 

8.             WITHHOLDING
TAXES.

 

8.1.          Withholding
Generally. As a condition of the grant, vesting and exercise of an Award granted
under this Plan, the Company may require the Participant (or in the case of the Participant’s death or a permitted transferee,
the person holding or exercising the Award) to remit to the Company an amount sufficient to satisfy federal, state and local withholding
tax requirements prior to the delivery of any certificate or certificates for such Shares. The Company shall not be required to
issue any Shares under the Plan until such obligations are satisfied. Whenever, under this Plan, payments in satisfaction of Awards
are to be made in cash by the Company, such payment will be net of an amount sufficient to satisfy federal, state, and local withholding
tax requirements.

 

    9

     

    

 

8.2.          Stock
Withholding. When, under applicable tax laws, a Participant (or in the case of Participant’s
death or a permitted transferee, the person holding or exercising the Award) incurs tax liability in connection with the exercise
or vesting of any Award that is subject to tax withholding and the Participant is obligated to pay the Company the amount required
to be withheld, the Committee may in its sole discretion allow the Participant to satisfy the minimum withholding tax obligation
by electing to have the Company withhold from the Shares to be issued that number of Shares having a Fair Market Value equal to
the minimum amount required to be withheld, determined on the date that the amount of tax to be withheld is to be determined.
All elections by a Participant to have Shares withheld for this purpose will be made in accordance with the requirements established
by the Committee for such elections and be in writing in a form acceptable to the Committee.

 

9.             PRIVILEGES
OF STOCK OWNERSHIP.

 

9.1.          Voting
and Dividends. No Participant will have any of the rights of a stockholder with respect
to any Shares until the Shares are issued to the Participant. After Shares are issued to the Participant, the Participant will
be a stockholder and have all the rights of a stockholder with respect to such Shares, including the right to vote and receive
all dividends or other distributions made or paid with respect to such Shares; provided, that the Participant will have no right
to retain such stock dividends or stock distributions with respect to Unvested Shares that are repurchased pursuant to Sections
5.12 or 6.2 hereof. The Company will comply with Section 260.140.01 of Title 10 of the California Code of Regulations with
respect to the voting rights of Common Stock.

 

9.2.          Financial
Statements. If required under Applicable Laws, the Company will provide financial
statements to each Participant annually during the period such Participant has Awards outstanding.

 

10.           TRANSFERABILITY
OF AWARDS. Unless otherwise provided in an Option Agreement or Restricted Stock Agreement,
Awards granted under this Plan, and any interest therein, will not be pledged, assigned, hypothecated, transferred or disposed
of by Participant, other than by will or by the laws of descent and distribution and may not be made subject to execution, attachment
or similar process. During the lifetime of the Participant, an Award will be exercisable only by the Participant or Participant’s
legal representative and any elections with respect to an Award may be made only by the Participant or Participant’s legal
representative. The designation of a beneficiary by a Participant will not constitute a transfer.

 

    10

     

    

 

11.           CERTIFICATES.
All certificates for Shares or other securities delivered under this Plan will be subject to such stock transfer orders, legends
and other restrictions as the Committee may deem necessary or advisable, including restrictions under any applicable federal,
state or foreign securities law, or any rules, regulations and other requirements of the SEC or any stock exchange or automated
quotation system upon which the Shares may be listed or quoted.

 

12.           ESCROW;
PLEDGE OF SHARES. To enforce any restrictions on a Participant’s Shares set
forth in Sections 5.12 or 6.2 hereof, the Committee may require the Participant to deposit all certificates representing Shares,
together with stock powers or other instruments of transfer approved by the Committee, appropriately endorsed in blank, with the
Company or an agent designated by the Company to hold in escrow until such restrictions have lapsed or terminated. The Committee
may cause a legend or legends referencing such restrictions to be placed on the certificates. Any Participant who is permitted
to execute a promissory note as partial or full consideration for the purchase of Shares under this Plan will be required to pledge
and deposit with the Company all or part of the Shares so purchased as collateral to secure the payment of Participant’s
obligation to the Company under the promissory note; provided, however, that the Committee may require or accept other or additional
forms of collateral to secure the payment of such obligation and, in any event, the Company will have full recourse against the
Participant under the promissory note notwithstanding any pledge of the Participant’s Shares or other collateral. In connection
with any pledge of the Shares, Participant will be required to execute and deliver a written pledge agreement in such form as
the Committee will from time to time approve.

 

13.    
       EXCHANGE AND BUYOUT OF OPTIONS.
The Committee may, at any time or from time to time, authorize the Company, with the consent of the respective Participants,
to issue new Options in exchange for the surrender and cancellation of any or all outstanding Options. The Committee may at
any time buy from a Participant an Option previously granted with payment in cash, shares of Common Stock of the Company or
other consideration, based on such terms and conditions as the Committee and the Participant may agree.

 

14.           SECURITIES
LAW AND OTHER REGULATORY COMPLIANCE. This Plan is intended to comply with Section 25102(o) of
the California Corporations Code. Any provision of this Plan which is inconsistent with Section 25102(o) shall, without
further act or amendment by the Company or the Board, be reformed to comply with the requirements of Section 25102(o). An
Award will not be effective unless such Award is in compliance with all applicable foreign, federal and state securities laws,
rules and regulations of any governmental body, and the requirements of any stock exchange or automated quotation system
upon which the Shares may then be listed or quoted, as they are in effect on the date of grant of the Award and also on the date
of exercise or other issuance. Notwithstanding any other provision in this Plan, the Company will have no obligation to issue
or deliver certificates for Shares under this Plan prior to (i) obtaining any approvals from governmental agencies that the
Company determines are necessary or advisable, and/or (ii) compliance with any exemption, completion of any registration
or other qualification of such Shares under any state, federal or foreign law or ruling of any governmental body that the Company
determines to be necessary or advisable. The Company will be under no obligation to register the Shares with the SEC or to effect
compliance with the exemption, registration, qualification or listing requirements of any foreign or state securities laws, stock
exchange or automated quotation system, and the Company will have no liability for any inability or failure to do so.

 

    11

     

    

 

15.           NO
OBLIGATION TO EMPLOY. Nothing in this Plan or any Award granted under this Plan will
confer or be deemed to confer on any Participant any right to continue in the employ of, or to continue any other relationship
with, the Company or any Parent or Subsidiary of the Company, be deemed to modify any Participant’s “at-will”
status with the Company, or limit in any way the right of the Company or any Parent or Subsidiary of the Company to terminate
Participant’s employment or other relationship at any time, with or without cause.

 

16.           CORPORATE
TRANSACTIONS.

 

16.1.          Dissolution
or Liquidation. In the event of the dissolution or liquidation of the Company, each
Award will terminate immediately prior to the consummation of such action, unless otherwise determined by the Committee.

 

16.2.          Assumption
or Replacement of Options by Successor or Acquiring Company. In the event of (i) a
merger or consolidation in which the Company is not the surviving corporation, (ii) a merger in which the Company is the
surviving corporation but after which the stockholders of the Company immediately prior to such merger (other than any stockholder
which merges with the Company in such merger, or which owns or controls another corporation which merges with the Company in such
merger) cease to own their shares or other equity interests in the Company, or (iii) the sale of all or substantially all
of the assets of the Company, any or all outstanding Options may be assumed, converted or replaced by the successor or acquiring
corporation (if any), which assumption, conversion or replacement will be binding on all Participants. In the alternative, the
successor or acquiring corporation may substitute equivalent Options or provide substantially similar consideration to Participants
as was provided to stockholders (after taking into account the existing provisions of the Options). The successor or acquiring
corporation may also substitute by issuing, in place of outstanding Shares of the Company held by the Participant, substantially
similar shares or other property subject to repurchase restrictions and other provisions no less favorable to the Participant
than those which applied to such outstanding Shares immediately prior to such transaction described in this Section 16.2.

 

16.3.          Failure
to Assume. In the event such successor or acquiring corporation (if any) refuses
to assume, convert, replace or substitute Options, as provided above, pursuant to a transaction described in Section 16.2,
then notwithstanding any other provision in this Plan to the contrary, such Options will expire on such transaction at such time
and on such conditions as the Committee will determine. The Committee shall notify the Participant that the Option will terminate
at least five (5) days prior to the date on which the Option terminates. If any outstanding Option held by a current Participant
is to be terminated (in whole or in part) pursuant to this paragraph, the Committee may, in its sole discretion, elect to accelerate
the vesting and exercisability of each such Option such that the Option shall become vested and exercisable in full or part prior
to the consummation of such transaction at such time and on such conditions as the Committee shall determine in its sole discretion.

 

16.4.          Other
Treatment of Options. Subject to any greater rights granted to Participants under
the foregoing provisions of this Section 16 hereof, in the event of the occurrence of any transaction described in Section 16.2
hereof, any outstanding Options will be treated as provided in the applicable agreement or plan of merger, consolidation, dissolution,
liquidation or sale of assets.

 

    12

     

    

 

16.5.          Assumption
of Options by the Company. The Company, from time to time, also may substitute or
assume outstanding options granted by another company, whether in connection with an acquisition of such other company or otherwise,
by either (i) granting an Option under this Plan in substitution of such other company’s option, or (ii) assuming
such option as if it had been granted under this Plan if the terms of such assumed option could be applied to an Option granted
under this Plan. Such substitution or assumption will be permissible if the holder of the substituted or assumed option would
have been eligible to be granted an Option under this Plan if the other company had applied the rules of this Plan to such
grant. In the event the Company assumes an option granted by another company, the terms and conditions of such option will remain
unchanged (except that the exercise price and the number and nature of shares issuable upon exercise of any such option
will be adjusted appropriately pursuant to Section 424(a) of the Code). In the event the Company elects to grant a new
Option rather than assuming an existing option, such new Option may be granted with a similarly adjusted Exercise Price.

 

16.6.          Parachute
Payments. Notwithstanding anything in any Option Agreement or Restricted Stock Agreement
to the contrary, if any of such agreements provide for acceleration of the vesting of Shares or other actions with respect to
the Shares underlying such agreement (which actions could be deemed a “payment” within the meaning of 280G(b)(2) of
the Internal Revenue Code of 1986, as amended (the “Code”)), together with any other payments that the
Participant has the right to receive from the Company or any entity which is a member of an “affiliated group” (as
defined in Section 1504(a) of the Code without regards to Section 1504(b) of the Code) of which the Company
is a member, would constitute a “parachute payment” (as defined in Section 280G(b)(2) of the Code), such
deemed “payments” will be reduced to the largest amount as will result in no portion of such deemed “payments”
being subject to the excise tax imposed by Section 4999 of the Code; provided, however, that such “payments”
shall only be reduced if such reduction would result in Participant receiving a greater net benefit, on an after-tax basis (including
after payment of any excise tax imposed by Section 4999 of the Code), than Participant would have received had such reduction
not occurred.

 

17.           ADOPTION
AND STOCKHOLDER APPROVAL. This Plan will become effective on the date that it is
adopted by the Board (the “Effective Date”). This Plan will be approved by the stockholders of the Company
(excluding Shares issued pursuant to this Plan), consistent with Applicable Laws, within twelve (12) months before or after the
Effective Date. Upon the Effective Date, the Committee may grant Awards pursuant to this Plan; provided, however, that: (i) no
Option may be exercised or Restricted Stock purchased prior to initial stockholder approval of this Plan; (ii) no Option
or Restricted Stock granted pursuant to an increase in the number of Shares approved by the Committee shall be exercised or purchased,
as applicable prior to the time such increase has been approved by the stockholders of the Company; (iii) in the event that
initial stockholder approval is not obtained within the time period provided herein, all Awards granted hereunder shall be canceled,
any Shares issued pursuant to any Award, whether by exercise of an Option or purchase of Restricted Stock, shall be canceled and
rescinded; and (iv) Options granted pursuant to an increase in the number of Shares approved by the Board which increase
is not timely approved by stockholders shall be canceled.

 

    13

     

    

 

18.           TIME
OF GRANTING AWARDS. The date of grant of an Award shall, for all purposes, be the
date on which the Committee makes the determination granting such Award, or such other date as is determined by the Committee,
provided that in the case of any ISO, the grant date shall be the later of the date on which the Committee makes the determination
granting such ISO or the date of commencement of the Participant’s employment relationship with the Company.

 

19.           TERM
OF PLAN/GOVERNING LAW.  Unless earlier terminated as provided herein, this Plan will
terminate ten (10) years from the Effective Date or, if earlier, the date of stockholder approval. This Plan and all agreements
hereunder shall be governed by and construed in accordance with the laws of the State of Delaware.

 

20.           AMENDMENT
OR TERMINATION OF PLAN. Subject to Section 5.9 hereof, the Board may at any
time terminate or amend this Plan in any respect, including without limitation amendment of any form of Option Agreement, Restricted
Stock Purchase Agreement or instrument to be executed pursuant to this Plan. No amendment of the Plan shall be made that would
materially and adversely affect the rights of any Participant under any outstanding Award, without his or her consent. The Board
will not, without the approval of the stockholders of the Company, amend this Plan in any manner that requires such stockholder
approval pursuant to Section 25102(o) of the California Corporations Code or the Code or the regulations promulgated
thereunder as such provisions apply to ISO plans.

 

21.           NONEXCLUSIVITY
OF THE PLAN. Neither the adoption of this Plan by the Board, the submission of this
Plan to the stockholders of the Company for approval, nor any provision of this Plan will be construed as creating any limitations
on the power of the Board to adopt such additional compensation arrangements as it may deem desirable, including, without limitation,
the granting of stock options and other equity awards otherwise than under this Plan, and such arrangements may be either generally
applicable or applicable only in specific cases.

 

22.           BENEFICIARIES.
Unless stated otherwise in an Award agreement, a Participant may designate one or more beneficiaries with respect to an Award
by timely filing the prescribed form with the Company. A beneficiary designation may be changed by filing the prescribed form
with the Company at any time before the Participant’s death. If no beneficiary was designated or if no designated beneficiary
survives the Participant, then after a Participant’s death and vested Awards shall be transferred or distributed to the
Participant’s estate.

 

23.           DEFINITIONS.
As used in this Plan, the following terms will have the following meanings:

 

“Applicable
Laws” means all applicable laws, rules, regulations and requirements, including, but not limited to, all applicable
U.S. federal or state laws, any stock exchange rules or regulations, and the applicable laws, rules or regulations of
any other country or jurisdiction where Awards are granted under the Plan or Participants reside or provide services, as such laws,
rules and regulations shall be in effect from time to time.

 

    14

     

    

 

“Award”
means any award of an Option or Restricted Stock under the Plan.

 

“Board”
means the Board of Directors of the Company.

 

“Cause”
means, unless otherwise defined in an Option Agreement or Restricted Stock Purchase Agreement, (i) any willful, material violation
by Participant of any law or regulation applicable to the business of the Company (or any successor, subsidiary, parent or affiliate
of the Company), (ii) Participant’s conviction for, or guilty or nolo contendere plea to, any felony or any willful
perpetration by Participant of a common law fraud, (iii) Participant’s commission of an act of personal dishonesty which
involves personal profit in connection with the Company (or any successor, subsidiary, parent or affiliate of the Company) or any
other entity having a material business relationship with the Company, (iv) a repeated pattern of unexcused absences that
causes substantial failure by Participant to perform the material duties as a director, officer, employee or consultant of the
Company, (v) any continued failure or refusal by Participant to perform the material, lawful, duties required of Participant
in his capacity as a director, officer, employee or consultant of the Company (or any successor, subsidiary, parent or affiliate
of the Company if Participant is then primarily employed by such entity) after written notice or (vi) a material breach of
any applicable invention assignment and/or confidentiality agreement or similar agreement that materially damages the Company (or
any successor, subsidiary, parent or affiliate of the Company). The determination as to whether a Participant has been Terminated
for Cause shall be made in good faith by the Committee and shall be final and binding on the Participant. The foregoing definition
does not in any way limit the Company’s ability to terminate a Participant’s employment or consulting relationship
at any time and the term “Company” will be interpreted to include any Subsidiary, Parent, Affiliate, or any successor
thereto, if appropriate.

 

“Change
of Control” means, unless otherwise defined in an Option Agreement or Restricted Stock Purchase Agreement,
(i) any merger or consolidation in which the Company shall not be the surviving entity (or survives only as a subsidiary of
another entity whose stockholders did not own all or substantially all of the stock of the Company in substantially the same proportions
as immediately prior to such transaction), (ii) the sale of all or substantially all of the Company’s assets to any
other person or entity (other than a sale to a wholly-owned subsidiary or a sale of one or more business lines of the Company such
that the Company does not liquidate and continues to operate at least one business line after such sale), or (iii) the acquisition
of beneficial ownership of a controlling interest (including, without limitation, power to vote) the outstanding shares of stock
of the Company by any person or entity (including a “group” as defined by or under Section 13(d)(3) of the
Securities Exchange Act of 1934, as amended.

 

“Code”
means the Internal Revenue Code of 1986, as amended.

 

“Committee”
means the committee created and appointed by the Board to administer this Plan, or if no such committee is created and appointed,
the Board.

 

    15

     

    

 

“Company”
means Edgewise Therapeutics, Inc., a Delaware corporation, or any successor corporation.

 

“Common
Stock” means the Company’s common stock, par value $0.00001 per share, as adjusted pursuant to Sections
2 and 16 hereof, and any successor security.

 

“Disability”
means disability, within the meaning of Section 22(e)(3) of the Code.

 

“Effective
Price” is defined in Section 17 herein.

 

“Exercise
Agreement” is defined in Section 5.5 herein.

 

“Exercise
Price” means the price at which a holder of an Option may purchase the Shares issuable upon exercise of the
Option.

 

“Fair
Market Value” means, as of any date, the value of a share of Common Stock determined as follows:

 

(a)          if
the Common Stock is publicly traded and listed on a national securities exchange, its closing price on the date of determination
on the principal national securities exchange on which the Common Stock is listed or admitted to trading, as reported in The
Wall Street Journal;

 

(b)          if
the Common Stock is publicly traded but is not listed or admitted to trading on a national securities exchange, the average of
the closing bid and asked prices on the date of determination as reported by The Wall Street Journal (or, if not so reported,
as otherwise reported by any newspaper or other source as the Committee may determine); or

 

(c)          if
none of the foregoing is applicable, by the Committee as applied consistently with respect to the Participants.

 

“Good
Reason” means, unless otherwise defined in an Option Agreement or Restricted Stock Purchase Agreement,
(i) the assignment to Participant of duties, or limitation of Participant’s responsibilities, materially inconsistent
with his position, duties, responsibilities and status with the Company, provided that neither a mere change in title alone
nor reassignment following a Change in Control to a position that is substantially similar to the position held prior to the transaction
shall constitute Good Reason, (ii) a material reduction by the Company of Participant’s annual base salary, unless
such reduction affects all similarly situated employees, or (iii) the relocation of Participant’s principal place of
employment to a location that is more than fifty (50) miles further from Participant’s current principal place of employment;
provided however, that in order for circumstances to provide Good Reason for Participant’s resignation, the following
additional conditions must be satisfied also: (A) Participant resigns within six (6) months after the initial occurrence
of the circumstance giving rise to Good Reason; (B) Participant provides notice to the Company of the circumstance giving
rise to Good Reason within ninety (90) days after the initial existence of such circumstance; and (C) the Company has a thirty
(30) day period in which to cure such circumstance, if it is capable of being cured, and upon any such cure, Participant shall
not be considered to have Good Reason to resign. The determination as to whether a Participant has resigned for Good Reason shall
be made in good faith by the Committee and shall be final and binding on the Participant. The term “Company” will
be interpreted to include any Subsidiary, Parent, Affiliate, or any successor thereto, if appropriate.

 

    16

     

    

 

 

“ISO”
is defined in Section 5 above.

 

“NQSO”
is defined in Section 5 above.

 

“Option”
means an award of an option to purchase Shares pursuant to Section 5.

 

“Option
Agreement” means a written document, the form(s) of which shall be approved from time to time by the
Committee, reflecting the terms of an Option granted under the Plan and includes any documents attached to such agreement.

 

“Option
Exchange Program” means a program approved by the Committee whereby outstanding Options (i) are exchanged
for Options with a lower exercise price or Restricted Stock or (ii) are amended to decrease the exercise price as a result
of a decline in the Fair Market Value of the Common Stock.

 

“Parent”
means any corporation (other than the Company) in an unbroken chain of corporations ending with the Company if, at the time of
the grant of the Award, each of such corporations other than the Company owns stock representing fifty percent (50%) or more of
the total combined voting power of all classes of stock in one of the other corporations in such chain; provided, however, that
the Committee shall have the discretion to determine that an entity otherwise meeting such definition is not a Parent for purposes
of this Plan. A corporation that attains the status of Parent on a date after the adoption of the Plan shall be considered a Parent
commencing as of such date.

 

“Participant”
means a person who receives an Award under this Plan.

 

“Plan”
means this 2017 Equity Incentive Plan, as amended from time to time.

 

“Purchase
Price” means the price at which Shares may be purchased pursuant to a Restricted Stock Purchase Agreement.

 

“Restricted
Stock” means Shares acquired pursuant to a right to purchase Shares granted pursuant to Section 6.

 

“Restricted
Stock Purchase Agreement” means a written document, the form(s) of which shall be approved from time
to time by the Committee, reflecting the terms of Restricted Stock granted under the Plan and includes any documents attached to
such agreement.

 

“SEC”
means the Securities and Exchange Commission.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

    17

     

    

 

“Shares”
means the shares of Common Stock reserved for issuance under this Plan, as adjusted pursuant to Sections 2 and 16 hereof, and any
successor security.

 

“Subsidiary”
means any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company if, at the time
of the grant of the Award, each of the corporations other than the last corporation in the unbroken chain owns stock representing
fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such
chain. A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary
commencing as of such date.

 

“Termination”
or “Terminated” means, for purposes of this Plan with respect to a Participant, that the Participant
has for any reason ceased to provide services as an employee, officer, director or consultant to the Company or a Parent or Subsidiary
of the Company, as determined in the sole discretion of the Committee. A Participant will not be deemed to have ceased to provide
services in the case of (i) sick leave, (ii) military leave, or (iii) any other leave of absence approved by the
Committee, provided that such leave is for a period of not more than ninety (90) days (a) unless reinstatement (or, in the
case of an employee with an ISO, reemployment) upon the expiration of such leave is guaranteed by contract or statute, or (b) unless
provided otherwise pursuant to formal policy adopted from time to time by the Company’s Board and issued and promulgated
in writing. In the case of any Participant on (i) sick leave, (ii) military leave or (iii) an approved leave of
absence, the Committee may make such provisions respecting suspension of vesting of the Award while on leave from the Company or
a Parent or Subsidiary of the Company as it may deem appropriate, except that in no event may an Award be exercised after the expiration
of the term set forth in the Option Agreement or Restricted Stock Purchase Agreement, as applicable. The Committee will have sole
discretion to determine when and whether a Participant has ceased to provide services to the Company.

 

“Termination
Date” means the date of Termination of a Participant. The Committee will have sole discretion to determine
the Termination Date of a Participant.

 

“Unvested
Shares” means shares that have not vested pursuant to the vesting schedule set forth in a Option Agreement
or for which the Company’s repurchase option has not lapsed pursuant to a Restricted Stock Purchase Agreement.

 

“Vested
Shares” means shares that have vested pursuant to the vesting schedule set forth in the Option Agreement or
for which the Company’s repurchase option has lapsed pursuant to a Restricted Stock Purchase Agreement.

 

    18

     

    

 

PLAN HISTORY

 

		1.	Adopted by the Board of Directors and Stockholders on June 5, 2017 (1,676,471 shares reserved)

 

		2.	Amended by the Board of Directors and Stockholders on August 9, 2018 (1,676,471 shares to 3,441,176 shares)

 

		3.	Amended by the Board of Directors and Stockholders on August 26, 2019 (3,441,176 shares to 5,722,349 shares)

 

		4.	Amended by the Board of Directors on August 6, 2020 and by the Stockholders on August 10, 2020 (5,722,349 shares
to 7,762,949 shares)

 

		5.	Amended by the Board of Directors and by the Stockholders on November 30, 2020 (7,762,949 shares to 12,585,602 shares)

 

    

     

    

 

NOTICE OF STOCK OPTION GRANT

 

PURSUANT TO THE

EDGEWISE THERAPEUTICS, INC.

2017 EQUITY INCENTIVE PLAN

 

	 	 
	 (Name)	 
	 	 
	 	 
	 (Address)	 
	 	 
	 	 
	 (Address)

  (Please note any corrections to the address above)	 

 

You (the “Optionee”)
have been granted an option (the “Option”) to purchase Common Stock of Edgewise Therapeutics, Inc.,
a Delaware corporation (the “Company”), as follows. This Option is granted under and governed by the
terms and conditions of the Company’s 2017 Equity Incentive Plan (the “Plan”) and the Stock Option
Agreement, both of which are attached as Annex I and Annex II hereto, respectively, and made a part of this document.
Unless otherwise defined herein, any capitalized terms used herein shall have the meanings ascribed to such terms in the Plan.

 

	Board Approval Date:	 
	 	 
	Date of Grant (Later of Board	 
	Approval Date or Commencement	 
	of Employment/Consulting):	 
	 	 
	Vesting Commencement Date:	 
	 	 
	Exercise Price per Share:	 
	 	 
	Total Number of Shares Granted:	(the “Shares”)
	 	 
	Total Exercise Price:	 
	 	 
	Type of Option:	 	  Incentive Stock Option
	 	 	 
	 	 	  Non-Qualified Stock Option
	 	 	 
	Expiration Date:	 

 

    1

     

    

 

	Vesting Schedule:	
        This Option may be exercised, in whole
        or in part, as follows: [______]

         

        No Shares shall become exercisable after
        Optionee’s Termination from the Company. Optionee shall in no event be entitled under this Option to purchase a number of
        shares of the Company’s Common Stock greater than the “Total Number of Shares Granted” indicated above. If the
        application of this vesting schedule results in a fractional share, such share shall be rounded down to the nearest whole share
        for each month except for the last month of the Vesting Schedule when the balance of all Shares shall become exercisable.

         

	Termination Period:	To the extent this Option is vested and exercisable as of the Termination Date, this Option may be exercised for a period of up to 90 days after Optionee’s Termination, except as set forth in Sections 6 and 7 of the Stock Option Agreement or as otherwise provided in the Plan (but in no event later than the Expiration Date set forth above).

 

    2

     

    

 

By your signature and
the signature of the Company’s representative below, you agree that you have received a copy of the Plan and the Stock Option
Agreement, and you and the Company agree that the Option described herein shall be subject to the terms of each of such document.

 

	OPTIONEE	 	EDGEWISE THERAPEUTICS, INC.

 

	 	 	By:	 
	Name:	 		Name:
	 	 		Title:

 

Signature Page to Edgewise Therapeutics, Inc.

Notice of Stock Option Grant

 

    

     

    

 

ANNEX I TO NOTICE OF STOCK OPTION
GRANT

 

STOCK OPTION AGREEMENT

PURSUANT TO

EDGEWISE THERAPEUTICS, INC. 2017
EQUITY INCENTIVE PLAN

 

1.             Grant
of Option. Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants
to ________________ (“Optionee”), an option (the “Option”) to purchase up to
such number of shares of Common Stock (the “Shares”) as is set forth in the Notice of Stock Option Grant,
at the exercise price per share set forth in the Notice of Stock Option Grant (the “Exercise Price”),
subject in all cases to the terms, definitions and provisions of the Edgewise Therapeutics, Inc. 2017 Equity Incentive Plan
(the “Plan”) adopted by the Company, which is incorporated herein by reference. Unless otherwise defined
herein, any capitalized terms used herein shall have the meanings ascribed to such terms in the Plan.

 

If designated an Incentive
Stock Option, this Option is intended to qualify as an Incentive Stock Option as defined in Section 422 of the Internal Revenue
Code (the “Code”), provided, however, to the extent not so designated or if this Option does not qualify
as an Incentive Stock Option, it is intended to be a Nonstatutory Stock Option.

 

Notwithstanding the
above, in the event that the Shares subject to this Option and any other Incentive Stock Option granted to the Optionee become
exercisable for the first time by Optionee during any calendar year and have an aggregate fair market value (determined for each
Share as of the date of grant of each option covering such Share) in excess of $100,000, then the shares in excess of $100,000
shall be treated as subject to a Nonstatutory Stock Option in accordance with Section 5.8 of the Plan.

 

2.             Exercise
of Option. This Option shall be exercisable prior to the Expiration Date set forth in the Notice of Stock Option Grant
in accordance with the Vesting Schedule set out in the Notice of Stock Option Grant and with the provisions of Section 7 of
the Plan as follows:

 

(a)             Right
to Exercise.

 

(i)             This
Option may not be exercised for a fraction of a share.

 

(ii)             In
the event of Optionee’s death, Disability or other termination of employment, the exercisability of the Option is governed
by Sections 5, 6 and 7 below, subject to the limitations contained in Section 2(a)(iii) below.

 

(iii)             In
no event may this Option be exercised after the Expiration Date of this Option as set forth in the Notice of Stock Option Grant.

 

    1

     

    

 

(b)             Method
of Exercise. This Option shall be exercisable by execution and delivery of the Exercise Notice attached hereto as Exhibit A
(the “Exercise Notice”) or of any other form of written notice approved for such purpose by the Company,
in its sole discretion, which shall state the election to exercise the Option, the number of Shares in respect of which the Option
is being exercised, and such other representations and agreements as to the holder’s investment intent with respect to such
shares of Common Stock as may be required by the Company pursuant to the provisions of the Plan. Such written notice shall be signed
by Optionee and shall be delivered in person or by certified mail to the Secretary of the Company. The written notice shall be
accompanied by payment of the Exercise Price. This Option shall be deemed to be exercised upon receipt by the Company of such written
notice accompanied by the Exercise Price.

 

No Shares will be issued
pursuant to the exercise of an Option unless such issuance and such exercise shall comply with all relevant provisions of applicable
law and the requirements of any stock exchange upon which the Shares may then be listed. Assuming such compliance, for income tax
purposes the Shares shall be considered transferred to Optionee on the date on which the Option is exercised with respect to such
Shares.

 

3.             Method
of Payment. Payment of the Exercise Price shall be by any of the following, or a combination thereof, at the election of
Optionee by:

 

(a)             cash
or check;

 

(b)             cancellation
of indebtedness of the Company to Optionee;

 

(c)             only
with the approval of the Committee, which may be withheld in its sole discretion, by tender of a full recourse promissory note
having such terms as may be approved by the Committee and bearing interest at a rate sufficient to avoid imputation of income under
Sections 483 and 1274 of the Code; 

 

(d)             only
with the approval of the Committee, which may be withheld in its sole discretion, surrender of shares of Common Stock of the Company
that have a Fair Market Value on the date of surrender equal to the Exercise Price of the Shares as to which the Option is
being exercised; or

 

(e)             if
there is a public market for the Shares and they are registered under the Securities Exchange Act, of 1934, as amended, delivery
of a properly executed exercise notice together with irrevocable instructions to a broker to deliver promptly to the Company the
amount of sale or loan proceeds required to pay the Exercise Price, such notice to be in a form approved by the Committee.

 

4.             Restrictions
on Exercise. This Option may not be exercised until such time as the Plan has been approved by the stockholders of the
Company, or if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute
a violation of any applicable federal or state securities or other law or regulation, including any rule under Part 221
of Title 12 of the Code of Federal Regulations as promulgated by the Federal Reserve Board. As a condition to the exercise
of this Option, the Company may require Optionee to make any representation and warranty to the Company as may be required by any
applicable law or regulation.

 

    2

     

    

 

5.             Termination
of Relationship. In the event of Termination of Optionee, Optionee may, to the extent otherwise so entitled at the Termination
Date, exercise this Option during the Termination Period set forth in the Notice of Stock Option Grant or otherwise provided for
in the Plan. To the extent that Optionee was not entitled to exercise this Option at such Termination Date, or if Optionee does
not exercise this Option within such Termination Period, the Option shall terminate.

 

6.             Disability
of Optionee.

 

(a)             Notwithstanding
the provisions of Section 5 above, in the event of Termination of Optionee as a result of Optionee’s total and permanent
Disability, Optionee may, but only within twelve (12) months from the Termination Date (but in no event later than the Expiration
Date set forth in the Notice of Stock Option Grant), exercise this Option to the extent Optionee was entitled to exercise it as
of such Termination Date. To the extent that Optionee was not entitled to exercise the Option as of the Termination Date, or if
Optionee does not exercise such Option (to the extent so entitled) within the time specified in this Section 6(a), the Option
shall terminate.

 

(b)             Notwithstanding
the provisions of Section 5 above, in the event of Termination of Optionee as a result of Disability not constituting a total
and permanent Disability, Optionee may, but only within six (6) months from the Termination Date (but in no event later than
the Expiration Date set forth in the Notice of Stock Option Grant), exercise the Option to the extent Optionee was entitled to
exercise it as of such Termination Date; provided, however, that if this is an Incentive Stock Option and Optionee fails to exercise
this Incentive Stock Option within three (3) months from the Termination Date, this Option will cease to qualify as an Incentive
Stock Option (as defined in Section 422 of the Code) and Optionee will be treated for federal income tax purposes as having
received ordinary income at the time of such exercise in an amount generally measured by the difference between the Exercise Price
for the Shares and the Fair Market Value of the Shares on the date of exercise. To the extent that Optionee was not entitled to
exercise the Option at the Termination Date, or if Optionee does not exercise such Option to the extent so entitled within the
time specified in this Section 6(b), the Option shall terminate.

 

7.             Death
of Optionee. In the event of the death of Optionee (a) during the term of this Option and while an employee or consultant
of the Company and having been in continuous status as an employee or consultant since the date of grant of the Option, or (b) within
thirty (30) days after Optionee’s Termination Date, the Option may be exercised at any time within six (6) months following
the date of death (but in no event later than the Expiration Date set forth in the Notice of Stock Option Grant), by Optionee’s
estate or by a person who acquired the right to exercise the Option by bequest or inheritance, but only to the extent of the right
to exercise that had accrued at the Termination Date.

 

    3

     

    

 

8.             Non-Transferability
of Option. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution
and may be exercised during the lifetime of Optionee only by him or her. The terms of this Option shall be binding upon the executors,
administrators, heirs, successors and assigns of Optionee.

 

9.             Term
of Option. This Option may be exercised only prior to the Expiration Date set forth in the Notice of Stock Option Grant,
subject to the limitations set forth in Section 5 of the Plan.

 

10.           Tax
Consequences.

 

(a)             Tax
Advice. OPTIONEE UNDERSTANDS THAT OPTIONEE MAY SUFFER ADVERSE TAX CONSEQUENCES AS A RESULT OF EXERCISE OF THIS OPTION
OR DISPOSITION OF THE SHARES EXERCISED. OPTIONEE REPRESENTS THAT OPTIONEE HAS CONSULTED WITH OR WILL CONSULT WITH ANY TAX CONSULTANT(S) OPTIONEE
DEEMS ADVISABLE PRIOR TO THE EXERCISE OF THIS OPTION OR DISPOSITION OF THE EXERCISED SHARES. OPTIONEE CONFIRMS THAT IT IS NOT RELYING
ON THE COMPANY FOR ANY TAX ADVICE.

 

(b)             Notice
of Disqualifying Disposition of Incentive Stock Option Shares. If the Option granted to Optionee herein is an Incentive
Stock Option, and if Optionee sells or otherwise disposes of any of the Shares acquired pursuant to the Incentive Stock Option
on or before the later of (i) the date two (2) years after the Date of Grant, or (ii) the date one (1) year
after the date of exercise, Optionee shall immediately notify the Company in writing of such disposition. Optionee acknowledges
and agrees that he or she may be subject to income tax withholding by the Company on the compensation income recognized by Optionee
from the early disposition by payment in cash or out of the current earnings paid to Optionee.

 

11.           Withholding
Tax Obligations. Prior to the issuance of the Shares upon exercise of this Option, Optionee must pay or make adequate
provision for any applicable federal or state withholding obligations of the Company. If Optionee is subject at the time of exercise
of this Option to Section 16(b) of the Exchange Act (an “Insider”), Optionee may provide for
payment of Optionee’s minimum statutory withholding taxes upon exercise of the Option by requesting that the Company retain
Shares with a Fair Market Value equal to the minimum amount of taxes required to be withheld, all as set forth in Section 8.2
of the Plan. In such case, the Company shall issue the net number of Shares to Optionee by deducting the Shares retained from
the Shares exercised.

 

12.           Market
Standoff Agreement. Optionee agrees in connection with any registration of the Company’s securities that, upon the
request of the Company or the underwriters managing any public offering of the Company’s securities, Optionee will not sell,
make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company (other
than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may
be, for such period of time after the effective date of such registration and subject to all restrictions as the Company or the
underwriters may specify for employee-shareholders generally. Optionee agrees to execute an agreement reflecting the foregoing
as may be requested by the underwriters at the time of the Company’s public offering. Optionee further agrees that the Company
may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period.

 

    4

     

    

 

13.           Limitations
on Transfer of Exercised Shares. In addition to any other limitation on transfer created by applicable securities laws,
following exercise of this Option, Optionee shall not assign, encumber or dispose of any interest in the exercised Shares except
in compliance with the provisions below and applicable securities laws.

 

(a)           Right
of First Refusal. Before any Shares exercised by Optionee or held by any transferee of Optionee (either being sometimes
referred to herein as the “Holder”) may be sold or otherwise transferred (including transfer by gift
or operation of law), the Company or its assignee(s) shall have a right of first refusal to purchase such Shares on the terms
and conditions set forth in this Section 13(a) (the “Right of First Refusal”).

 

(i)            Notice
of Proposed Transfer. The Holder of the Shares shall deliver to the Company a written notice (the “Notice”)
stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (ii) the name of each
proposed purchaser or other transferee (“Proposed Transferee”); (iii) the number of Shares to be
transferred to each Proposed Transferee; and (iv) the terms and conditions of each proposed sale or transfer. The Holder
shall offer the Shares at the same price (the “Offered Price”) and upon the same terms (or terms as
similar as reasonably possible) to the Company or its assignee(s).

 

(ii)           Exercise
of Right of First Refusal. At any time within 30 days after receipt of the Notice, the Company and/or its assignee(s) may,
by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred
to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection (iii) below.

 

(iii)           Purchase
Price. The purchase price (“Purchase Price”) for the Shares purchased by the Company or its
assignee(s) under this Section 13(a) shall be the Offered Price. If the Offered Price includes consideration other
than cash, the cash equivalent value of the non-cash consideration shall be determined by the Board of Directors of the Company
in good faith.

 

(iv)          Payment.
Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation
of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee,
to the assignee), or by any combination thereof within 30 days after receipt of the Notice or in the manner and at the times set
forth in the Notice.

 

    5

     

    

 

(v)           Holder’s
Right to Transfer. If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are not
purchased by the Company and/or its assignee(s) as provided in this Section 13(a), then the Holder may sell or otherwise
transfer such Shares to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other transfer
is consummated within 60 days after the date of the Notice and provided further that any such sale or other transfer is effected
in accordance with any applicable securities laws and the Proposed Transferee agrees in writing that the provisions of this Section 13
shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not
transferred to the Proposed Transferee within such period, or if the Holder proposes to change the price or other terms to make
them more favorable to the Proposed Transferee, a new Notice shall be given to the Company, and the Company and/or its assignees
shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred.

 

(vi)          Exception
for Certain Family Transfers. Anything to the contrary contained in this Section 13(a) notwithstanding, the
transfer of any or all of the Shares during Optionee’s lifetime or on Optionee’s death by will or intestacy to Optionee’s
Immediate Family (as defined below) or a trust for the benefit of Optionee’s Immediate Family shall be exempt from the provisions
of this Section 13(a). “Immediate Family” as used herein shall mean spouse, lineal descendant or
antecedent, father, mother, brother or sister. In such case, the transferee or other recipient shall receive and hold the Shares
so transferred subject to the provisions of this Section, and there shall be no further transfer of such Shares except in accordance
with the terms of this Section 13.

 

(b)           Involuntary
Transfer.

 

(i)            Company’s
Right to Purchase upon Involuntary Transfer. In the event, at any time after the date of this Agreement, of any transfer
by operation of law or other involuntary transfer (including divorce or death, but excluding, in the event of death, a transfer
to Immediate Family as set forth in Section 13(a)(vi) above) of all or a portion of the Shares by the record holder
thereof, the Company shall have the right to purchase all of the Shares transferred at the greater of the purchase price paid
by Optionee pursuant to this Agreement or the Fair Market Value of the Shares on the date of transfer (as determined below). Upon
such a transfer, the person acquiring the Shares shall promptly notify the Secretary of the Company of such transfer. The right
to purchase such Shares shall be provided to the Company for a period of 30 days following receipt by the Company of written notice
by the person acquiring the Shares.

 

(ii)           Price
for Involuntary Transfer. With respect to any stock to be transferred pursuant to Section 13(b)(i), “Fair
Market Value” shall mean the price per Share determined by the Board of Directors of the Company that will reflect
the current value of the stock in terms of present earnings and future prospects of the Company. The Company shall notify Optionee
or his or her executor of the price so determined within 30 days after receipt by it of written notice of the transfer or proposed
transfer of Shares. However, if Optionee does not agree with the valuation as determined by the Board of Directors of the Company,
Optionee shall be entitled to have the valuation determined by an independent appraiser to be mutually agreed upon by the Company
and Optionee and whose fees shall be borne equally by the Company and Optionee.

 

    6

     

    

 

(c)           Assignment.
The right of the Company to purchase any part of the Shares may be assigned in whole or in part to any stockholder or stockholders
of the Company or other persons or organizations.

 

(d)           Restrictions
Binding on Transferees. All transferees of Shares or any interest therein will receive and hold such Shares or interest
subject to the provisions of this Agreement. Any sale or transfer of the Shares shall be void unless the provisions of this Agreement
are satisfied.

 

(e)           Termination
of Rights. The Right of First Refusal and the Company’s right to repurchase the Shares in the event of an involuntary
transfer pursuant to Section 13(b) above shall terminate upon the first sale of Common Stock of the Company to the general
public pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission under the
Securities Act of 1933, as amended (the “Securities Act”).

 

14.           Ancillary
Agreements.

 

(a)             Voting
Agreement. As a condition to receipt of this Option, and concurrently with the execution
of this Option, Optionee hereby agrees that Optionee shall be deemed to be a “Common Holder” under, and shall be bound
by the provisions of, the Amended and Restated Voting Agreement dated December 3, 2020 by and among the Company and certain
equityholders of the Company party thereto, as such agreement may be amended, modified or superseded from time to time (the “Voting
Agreement”), including without limitation the drag-along provisions under such agreement. Optionee also agrees to
execute a counterpart signature page to the Voting Agreement concurrently with the execution of this Option or at any other
time if requested. A copy of the Voting Agreement is available from the Company.

 

(b)             Co-Sale
Agreement. In addition, Optionee hereby agrees that if Optionee now owns or shall at any time hereafter own one percent
(1%) or more of the Company’s then outstanding Common Stock (taking into account this Option and all other shares of Common
Stock, options and other purchase rights held by such employee, director or consultant and treating for this purpose all shares
of Common Stock issuable upon exercise of or conversion of outstanding options, warrants or convertible securities held by Optionee
and other parties, as if exercised or converted), as a condition to receipt of this Option, and concurrently with the execution
of this Option or at such time as Optionee exceeds such ownership threshold, Optionee shall be deemed to be a “Common Holder”
under, and shall be bound by the provisions of, the Amended and Restated Right of First Refusal and Co-Sale Agreement dated December 3,
2020 by and among the Company and certain equityholders of the Company party thereto, as such agreement may be amended, modified
or superseded from time to time (the “Co-Sale Agreement”), including without limitation the transfer
restrictions under such agreement. In such case, Optionee also agrees to execute a counterpart signature page to the Co-Sale
Agreement concurrently with the execution of this Option or at any other time if requested. A copy of the Co-Sale Agreement is
available from the Company.

 

    7

     

    

 

15.           Miscellaneous.

 

(a)             Governing
Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto
shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles
of conflicts of law.

 

(b)             Entire
Agreement; Enforcement of Rights. The Plan and the Option Notice are hereby incorporated by reference in this Agreement.
This Agreement (including the Plan and the Option Notice) sets forth the entire agreement and understanding of the parties relating
to the subject matter herein and merges all prior discussions between them. No modification of or amendment to this Agreement,
nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties to this Agreement.
The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such
party.

 

(c)             Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate
such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such
provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of the Agreement shall be
interpreted as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable in accordance
with its terms.

 

(d)             Construction.
This Agreement is the result of negotiations between and has been reviewed by each of the parties hereto and their respective counsel,
if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed
in favor of or against any one of the parties hereto.

 

(e)             Notices.
Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient when delivered personally
or sent by telegram or fax or 48 hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid,
and addressed to the party to be notified at such party’s address as set forth below or as subsequently modified by written
notice.

 

(f)              Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together
shall constitute one instrument.

 

(g)             Successors
and Assigns. The rights and benefits of this Agreement shall inure to the benefit of, and be enforceable by the Company’s
successors and assigns. The rights and obligations of Optionee under this Agreement may only be assigned with the prior written
consent of the Company.

 

(h)             No
Obligation to Continue Employment or Consultancy. Nothing in this Agreement will confer or be deemed to confer on Optionee
any right to continue in the employ of, or to continue any other relationship with, the Company, be deemed to modify Optionee’s
 “at-will” status with the Company, or limit in any way the right of the Company to terminate Optionee’s employment
or other relationship at any time, with or without cause.

 

    8

     

    

 

(i)              Incorporation
of Plan. This Option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of this
Option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated
and adopted by the Committee pursuant to the Plan. In the event of any conflict between the provisions of this Option and those
of the Plan, the provisions of the Plan shall control unless expressly provided in the Plan.

 

[Signature Page Follows.]

 

    9

     

    

 

This Agreement may
be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one
document.

 

	 	EDGEWISE THERAPEUTICS, INC.
	 	 
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

OPTIONEE ACKNOWLEDGES
AND AGREES THAT THE VESTING OF ANY SHARES ISSUED PURSUANT TO THIS OPTION IS EARNED ONLY BY CONTINUING EMPLOYMENT OR CONSULTANCY
AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER). OPTIONEE
FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE PLAN, WHICH IS INCORPORATED HEREIN BY REFERENCE, SHALL
CONFER UPON OPTIONEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT OR CONSULTANCY BY THE COMPANY, NOR SHALL IT INTERFERE
IN ANY WAY WITH OPTIONEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE OPTIONEE’S EMPLOYMENT OR CONSULTANCY AT
ANY TIME, WITH OR WITHOUT CAUSE.

 

Optionee acknowledges
receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts
this Option subject to all of the terms and provisions thereof. Optionee has reviewed the Plan and this Option in their entirety,
has had an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the
Option. Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon
any questions arising under the Plan or this Option.

 

	Dated:	 	 	
	 	 	Name:

  

Signature Page to Edgewise Therapeutics, Inc.

Stock Option Agreement

 

    

     

    

  

EXHIBIT A

 

NOTICE
OF EXERCISE

 

Edgewise Therapeutics, Inc.

3415 Colorado Ave

Boulder, CO 80303

 

Date of Exercise:
                    

 

Ladies and Gentlemen:

 

This constitutes notice
under my stock option identified below that I elect to purchase the number of shares of Common Stock of Edgewise Therapeutics, Inc.
(the “Company”) set forth below for the price set forth below.

 

	Type of option (check one):	 	Incentive   ̈	 	Nonstatutory   ̈
	 	 	 	 	 
	Stock option dated:	 	 	 	 
	 	 	 	 	 
	Number of shares as to which option is exercised:	 	 	 	 
	 	 	 	 	 
	Certificates to be issued in name of:	 	 	 	 
	 	 	 	 	 
	Total exercise price:	$		 	 
	 	 	 	 	 
	Cash payment delivered herewith:	$		 	 

 

By this exercise, I
agree (i) to provide such additional documents as the Company may require pursuant to the terms of its 2017 Equity Incentive
Plan, (ii) to provide for the payment by me to the Company (in the manner designated by the Company) of the Company’s
withholding obligation, if any, relating to the exercise of this option, and (iii) if this exercise relates to an incentive
stock option, to notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares
of Common Stock issued upon exercise of this option that occurs within two (2) years after the date of grant of this option
or within one (1) year after such shares of Common Stock are issued upon exercise of this option.

 

I hereby make the following
certifications and representations with respect to the number of shares of Common Stock of the Company listed above (the “Shares”),
which are being acquired by me for my own account upon exercise of the Option as set forth above:

 

    1

     

    

 

I am aware of the Company’s
business affairs and financial condition and have acquired sufficient information about the Company to reach an informed and knowledgeable
decision to acquire the Shares. I am purchasing the Shares for investment for my own account only and not with a view to, or for
resale in connection with, any “distribution” thereof within the meaning of the Securities Act of 1933, as amended
(the “Securities Act”).

 

I understand that the
Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these
laws, I must hold the Shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified
by state authorities, or an exemption from such registration and qualification requirements is available. I acknowledge that the
Company has no obligation to register or qualify the Shares for resale. I further acknowledge that if an exemption from registration
or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner
of sale, the holding period for the Shares, and requirements relating to the Company which are outside of my control, and which
the Company is under no obligation to and may not be able to satisfy.

 

I understand that I
may suffer adverse tax consequences as a result of my purchase or disposition of the Shares. I represent that I have consulted
any tax consultants I deem advisable in connection with the purchase or disposition of the Shares and that I am not relying on
the Company for any tax advice.

 

I understand that the
Shares are subject to a right of first refusal in favor of the Company, which is applicable on both voluntary and involuntary transfers
of the Shares, as set forth in Section 13 of the stock option agreement pursuant to which the Shares were issued. I understand
that the Shares may be subject to other restrictions on transfer or restrictions on voting. Any transferee of the Shares will be
subject to all such restrictions.

 

I further acknowledge
that all certificates representing any of the Shares subject to the provisions of the Option shall have endorsed thereon appropriate
legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company’s Certificate
of Incorporation, Bylaws and/or applicable securities laws.

 

I further agree that,
if required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of
the offering of any securities of the Company under the Securities Act, I will not sell or otherwise transfer or dispose of
any shares of Common Stock or other securities of the Company during such period (not to exceed one hundred eighty (180) days,
except that such period may be increased as reasonably deemed necessary by the managing underwriter(s) to comply with Conduct
Rule 2711 of the National Association of Securities Dealers or Rule 472 of the New York Stock Exchange or similar requirements)
following the effective date of the registration statement of the Company filed under the Securities Act as may be requested by
the Company or the representative of the underwriters. I further agree that the Company may impose stop-transfer instructions with
respect to securities subject to the foregoing restrictions until the end of such period.

 

    2

     

    

 

I further agree that
in connection with any registration of the Company’s securities that, upon the request of the Company or the underwriters
managing any public offering of the Company’s securities, I will not to sell, make any short sale of, loan, grant any
option for the purchase of, or otherwise dispose of any securities of the Company (other than those included in the registration)
without the prior written consent of the Company or such underwriters, as the case may be, for such period of time after the effective
date of such registration and subject to all restrictions as the Company or the underwriters may specify for employee-shareholders
generally. I agree to execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the
Company’s public offering. I further agree that the Company may impose stop-transfer instructions with respect to securities
subject to the foregoing restrictions until the end of such period.

 

 

	 	Very truly yours,
	 	 
	 	 
	 	 
	 	Name:
	 	 

 

    3

     

    

 

ANNEX II TO NOTICE OF STOCK OPTION
GRANT

 

EDGEWISE THERAPEUTICS, INC. 2017
EQUITY INCENTIVE PLAN

 

[Attached]

 

    4

     

    

 

EXHIBIT A

  

NOTICE
OF EXERCISE

 

Edgewise Therapeutics, Inc.

3415 Colorado Ave

Boulder, CO 80303

 

Date of Exercise:
                    

 

Ladies and Gentlemen:

 

This constitutes notice
under my stock options identified below that I elect to purchase the number of shares of Common Stock of Edgewise Therapeutics, Inc.
(the “Company”) set forth below for the prices set forth below.

 

	Option Grant Date	Total 

Shares	Exercise 

Price	Exercised

 Shares	Agg. Exercise

 Price
	 	 	 	 	 
	 	 	Total:	 	 

 

Each of the above-listed
stock options is an incentive stock option. All stock certificates issued in connection with the foregoing exercise shall be issued
in the following name: [______].

 

By this exercise, I
agree (i) to provide such additional documents as the Company may require pursuant to the terms of its 2017 Equity Incentive
Plan, (ii) to provide for the payment by me to the Company (in the manner designated by the Company) of the Company’s
withholding obligation, if any, relating to the exercise of these options, and (iii) if this exercise relates to an incentive
stock option, to notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares
of Common Stock issued upon exercise of these options that occurs within two (2) years after the date of grant of this option
or within one (1) year after such shares of Common Stock are issued upon exercise of these options.

 

I hereby make the following
certifications and representations with respect to the number of shares of Common Stock of the Company listed above (the “Shares”),
which are being acquired by me for my own account upon exercise of the options as set forth above:

 

I am aware of the Company’s
business affairs and financial condition and have acquired sufficient information about the Company to reach an informed and knowledgeable
decision to acquire the Shares. I am purchasing the Shares for investment for my own account only and not with a view to, or for
resale in connection with, any “distribution” thereof within the meaning of the Securities Act of 1933, as amended
(the “Securities Act”).

 

    1 

     

    

 

I understand that the
Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these
laws, I must hold the Shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified
by state authorities, or an exemption from such registration and qualification requirements is available. I acknowledge that the
Company has no obligation to register or qualify the Shares for resale. I further acknowledge that if an exemption from registration
or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner
of sale, the holding period for the Shares, and requirements relating to the Company which are outside of my control, and which
the Company is under no obligation to and may not be able to satisfy.

 

I understand that I
may suffer adverse tax consequences as a result of my purchase or disposition of the Shares. I represent that I have consulted
any tax consultants I deem advisable in connection with the purchase or disposition of the Shares and that I am not relying on
the Company for any tax advice.

 

I understand that the
Shares are subject to a right of first refusal in favor of the Company, which is applicable on both voluntary and involuntary transfers
of the Shares, as set forth in Section 13 of the stock option agreement pursuant to which the Shares were issued. I understand
that the Shares may be subject to other restrictions on transfer or restrictions on voting. Any transferee of the Shares will be
subject to all such restrictions.

 

I further acknowledge
that all certificates representing any of the Shares subject to the provisions of the Option shall have endorsed thereon appropriate
legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company’s Certificate
of Incorporation, Bylaws and/or applicable securities laws.

 

I further agree that,
if required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of
the offering of any securities of the Company under the Securities Act, I will not sell or otherwise transfer or dispose of
any shares of Common Stock or other securities of the Company during such period (not to exceed one hundred eighty (180) days,
except that such period may be increased as reasonably deemed necessary by the managing underwriter(s) to comply with Conduct
Rule 2711 of the National Association of Securities Dealers or Rule 472 of the New York Stock Exchange or similar requirements)
following the effective date of the registration statement of the Company filed under the Securities Act as may be requested by
the Company or the representative of the underwriters. I further agree that the Company may impose stop-transfer instructions with
respect to securities subject to the foregoing restrictions until the end of such period.

 

I further agree that
in connection with any registration of the Company’s securities that, upon the request of the Company or the underwriters
managing any public offering of the Company’s securities, I will not to sell, make any short sale of, loan, grant any
option for the purchase of, or otherwise dispose of any securities of the Company (other than those included in the registration)
without the prior written consent of the Company or such underwriters, as the case may be, for such period of time after the effective
date of such registration and subject to all restrictions as the Company or the underwriters may specify for employee-shareholders
generally. I agree to execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the
Company’s public offering. I further agree that the Company may impose stop-transfer instructions with respect to securities
subject to the foregoing restrictions until the end of such period.

 

	 	Very truly yours,
	 	 
	 	 
	 	 
	 	Name:

 

    2

     

    

 

RESTRICTED STOCK PURCHASE AGREEMENT

 

PURSUANT TO THE

EDGEWISE THERAPEUTICS, INC.

2017 EQUITY INCENTIVE PLAN

 

This Restricted Stock
Purchase Agreement (the “Agreement”) is made as of ________________ (the “Effective Date”)
by and between Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), and ________________
(“Holder”) pursuant to the Company’s 2017 Equity Incentive Plan (the “Plan”)
adopted by the Company, which is incorporated herein by reference. Unless otherwise defined herein, any capitalized terms used
herein shall have the meanings ascribed to such terms in the Plan.

 

The Company and Holder
hereby agree as follows:

 

1.             Purchase
of Shares. On this date and subject to the terms and conditions of this Agreement, Holder hereby purchases from the Company,
and the Company hereby sells to Holder, an aggregate of __________ shares of the Company’s Common Stock, par value $0.00001
per share (the “Shares”), at a purchase price of $______ per Share (the “Purchase Price”),
for a total purchase price of $______. The term “Shares” refers to the purchased Shares and all securities received
in replacement of or in connection with the Shares pursuant to stock dividends or splits, all securities received in replacement
of the Shares in a recapitalization, merger, reorganization, exchange or the like, and all new, substituted or additional securities
or other properties to which Holder is entitled by reason of Holder’s ownership of the Shares (collectively, “Share
Equivalents”).

 

2.             Representations
of Holder. Holder represents and warrants to the Company that:

 

(a)             Holder
is purchasing the Shares for Holder’s own account for investment purposes only and not with a view to, or for sale in connection
with, a distribution of the Shares within the meaning of the Securities Act of 1933, as amended (the “1933 Act”).

 

(b)             Holder
has no present intention of selling or otherwise disposing of all or any portion of the Shares.

 

(c)             Holder
has had access to all information regarding the Company and its present and prospective business, assets, liabilities and financial
condition that Holder reasonably considers important in making the decision to purchase the Shares, and Holder has had ample opportunity
to ask questions of the Company’s representatives concerning such matters and this investment.

 

(d)             Holder
is fully aware of (a) the highly speculative nature of the investment in the Shares; (b) the financial hazards involved;
(c) the lack of liquidity of the Shares and the restrictions on transferability of the Shares (e.g., that Holder may
not be able to sell or dispose of the Shares or use them as collateral for loans); and (d) the qualifications and backgrounds
of the principals of the Company.

 

    1 

     

    

 

(e)             Holder
is capable of evaluating the merits and risks of this investment, has the ability to protect Holder’s own interests in this
transaction and is financially capable of bearing a total loss of this investment.

 

(f)             Holder
has been advised that the purchase of and/or the disposition of the Shares hereunder may have adverse tax effects upon Holder.
Holder is not relying upon the Company or its legal counsel and has consulted with Holder’s own tax advisors in this regard.

 

3.             Compliance
with Federal Securities Laws. Holder understands and acknowledges that, in reliance upon the representations and warranties
made by Holder herein, the Shares have not been registered with the Securities and Exchange Commission (“SEC”)
under the 1933 Act, but have been issued under an exemption or exemptions from the registration requirements of the 1933 Act which
impose certain restrictions on Holder’s ability to transfer the Shares.

 

(a)             Restrictions
on Transfer. Holder understands that Holder may not transfer any Shares unless such Shares are registered under the 1933
Act or unless, in the opinion of counsel to the Company, an exemption from such registration is available. Holder understands
that only the Company may file a registration statement with the SEC and that the Company is under no obligation to do so with
respect to the Shares. Holder has also been advised that an exemption from registration may not be available or may not permit
Holder to transfer all or any of the Shares in the amounts or at the times proposed by Holder.

 

(b)             Rule 144.
In addition, Holder has been advised that SEC Rule 144 promulgated under the 1933 Act, which permits certain limited sales
of unregistered securities, is not presently available with respect to the Shares and, in any event, requires that the Shares
be held for certain minimum holding periods as set forth therein before they may be resold under Rule 144.

 

4.             Right
of Termination Unaffected. Nothing in this Agreement will be construed to limit or
otherwise affect in any manner whatsoever the right or power of the Company to terminate the services of Holder to the Company
at any time for any reason or no reason, with or without cause.

 

5.             Company’s
Right of Repurchase.

 

(a)             Repurchase
Option. The Company, or its assignee(s), shall have the option to repurchase all or a portion of the Shares on the terms
and conditions set forth in this Section 5 (the “Repurchase Option”) if the Holder is Terminated
for any reason (including death or disability), at any time within ninety (90) days after (the “Repurchase Period”)
the Holder’s Termination Date. Notwithstanding any other provision in this Agreement, the Company shall be deemed to have
timely exercised the Repurchase Option automatically for all of the Unvested Shares on the last day of the Repurchase Period unless
the Company at any time during the Repurchase Period notifies Holder that it will not exercise the Repurchase Right for some or
all of the Unvested Shares.

 

    2

     

    

 

(b)             Vesting
of Shares.

 

(i)            “Unvested
Shares” are Shares that are subject to the Company’s Repurchase Option in this Section 5. “Vested
Shares” are Shares that are no longer subject to the Company’s Repurchase Option in this Section 5. The
Shares shall vest [______]; provided, however, that such scheduled releases from the Repurchase Option shall immediately cease
as of the Termination Date. The “Vesting Commencement Date” shall mean [______]. If the application
of this vesting schedule results in a fractional share, such share shall be rounded down to the nearest whole share for each month
except for the last month of the vesting schedule, when the balance of all Unvested Shares shall become Vested Shares. The number
of Shares that are Vested Shares or Unvested Shares will be proportionally adjusted to reflect any stock dividend, stock split,
reverse stock split or recapitalization of the Common Stock of the Company occurring after the Effective Date as provided in the
Plan.

 

(ii)           Any
Share Equivalents received in respect of any Unvested Shares shall be subject to (a) the same vesting requirements applicable
to the Holder’s Unvested Shares and (b) such escrow arrangements as the Committee shall deem appropriate.

 

(iii)         Notwithstanding
the foregoing, in the event that prior to Holder’s Termination the Company undergoes a Change of Control, automatically
and without any further action on the part of the Company or Holder, one hundred percent (100%) of the then Unvested Shares shall
be deemed to be Vested Shares and no longer subject to the Repurchase Option.

 

(c)             Exercise
of Repurchase Option for Unvested Shares. At any time during the Repurchase Period,
the Company, or its assignee(s), may elect to repurchase all or a portion of the then Unvested Shares for a price equal to the
lesser of the Purchase Price per Share (as adjusted to reflect any stock dividend, stock split, reverse stock split or recapitalization
of the Common Stock of the Company occurring after the Effective Date) or the then current fair market value of each Share (as
determined in good faith by the Committee) by giving Holder written notice of exercise of the Repurchase Option. Unless the Company
shall have provided written notice to Holder during the Repurchase Period that it is not exercising the Repurchase Option with
respect to all or a portion of the Unvested Shares, the Company, or its assignee(s), shall be deemed to have elected to repurchase
all of the then Unvested Shares as of the last day of the Repurchase Period. If the Company shall have provided written notice
to Holder during the Repurchase Period that it is not exercising the Repurchase Option as to a portion of the Unvested Shares,
the Company, or its assignee(s), shall be deemed to have elected to repurchase the portion of the then Unvested Shares not subject
to such notice as of the date of such notice.

 

    3

     

    

 

(d)             Payment
of Repurchase Price. The repurchase price for the Unvested Shares shall be payable, at the option of the Company or its
assignee(s), by check or by cancellation of all or a portion of any outstanding indebtedness of Holder to the Company, or such
assignee(s), or by any combination thereof so that the combined payment and cancellation of indebtedness equals such purchase
price. The repurchase price shall be paid without interest within thirty (30) days after the exercise of the Repurchase Option.
Notwithstanding the Company’s obligation to pay such repurchase price, any Unvested Shares repurchased pursuant to the Repurchase
Option shall be deemed to have been repurchased as of the date of the exercise or deemed exercise of the Repurchase Option, and
the Company shall become the legal and beneficial owner of the Unvested Shares being repurchased and all rights and interest therein
or related thereto as of such date and the Holder shall have no rights in such Unvested Shares as of such date. Upon exercise
of the Repurchase Option, the Company shall have the right to transfer to its own name the number of Unvested Shares being repurchased
by the Company, without further action by Holder. If the Company or its assignee(s) shall fail to timely pay the repurchase
price to Holder, then the sole remedy of Holder shall be to seek payment of the repurchase price, and in no case shall Holder
have any claim of ownership or other right as to any of the Unvested Shares and such failure shall not affect the validity of
the exercise of the Company’s Repurchase Option.

 

6.             Rights
as Stockholder. Subject to the terms and conditions of this Agreement, Holder will have all of the rights of a shareholder
of the Company with respect to the Shares from and after the date that Holder delivers payment of the Purchase Price until such
time as Holder disposes of the Shares or such Shares are deemed repurchased pursuant to the Repurchase Option.

 

7.             Escrow.
As security for the faithful performance of Section 5, Holder agrees, immediately upon receipt of the certificate(s) evidencing
the Shares, to deliver such certificate(s), together with a stock power in the form of Exhibit A attached hereto,
executed by Holder and by Holder’s spouse, if any (with the date and number of Shares left blank), to the Secretary of the
Company or any other person designated by the Committee (“Escrow Holder”), who is hereby appointed to
hold such certificate(s) and stock power in escrow and to take all such actions and to effectuate all such transfers and/or
releases of such Shares as are in accordance with the terms of this Agreement. Holder and the Company agree that Escrow Holder
will not be liable to any party to this Agreement (or to any other party) for any actions or omissions unless Escrow Holder is
grossly negligent relative thereto. The Escrow Holder may rely upon any letter, notice or other document executed by any signature
purported to be genuine and may resign at any time. Holder hereby agrees that if Escrow Holder resigns for any or no reason, the
Committee shall have the power to appoint a successor to serve as Escrow Holder pursuant to the terms of this Agreement. The Escrow
Holder may rely on advice of counsel and obey any order of any court with respect to the transactions contemplated herein. The
Shares will be released from escrow upon termination of the Repurchase Option; provided, however, that such release will not affect
the rights of the Company with respect to any pledge of Shares to the Company.

 

    4

     

    

 

8.             Tax
Consequences. Holder understands that Section 83(a) of the Internal Revenue Code of 1986, as amended (the “Code”),
taxes as ordinary income the difference between the amount paid for the Shares and the fair market value of the Shares as of the
date any restrictions on the Shares lapse. In this context, “restriction” means the right of the Company to
buy back the Shares pursuant to the Repurchase Option set forth in Section 5 of this Agreement. Holder hereby acknowledges
that Holder may instead elect to be taxed at the time the Shares are purchased, rather than when and as the Repurchase Option
expires, by filing an election under Section 83(b) of the Code (an “83(b) Election”)
with the Internal Revenue Service and, if necessary, the proper state taxing authorities, within 30 days of the
purchase of the Shares. Even if the fair market value of the Shares at the time of the execution of this Agreement equals the
amount paid for the Shares, the 83(b) Election must be made to avoid income under Section 83(a) of the Code in
the future. Holder understands that the failure to file such an election in a timely manner may result in adverse tax consequences.
Holder represents that Holder has consulted any tax consultant(s) Holder deems advisable in connection with the purchase
of the Shares or the filing of the election under Section 83(b) of the Code and similar tax provisions. Holder further
understands that an additional copy of such election form should be filed with Holder’s federal income tax return for the
calendar year in which the date of this Agreement falls. A form of Section 83(b) Election is attached hereto as Exhibit B
for reference. HOLDER HEREBY ASSUMES ALL RESPONSIBILITY FOR FILING SUCH ELECTION AND PAYING ANY TAXES RESULTING FROM SUCH
ELECTION OR THE LAPSE OF THE REPURCHASE RESTRICTIONS ON THE UNVESTED SHARES.

 

9.             Limitations
on Transfer of Shares. In addition to any other limitation on transfer created by applicable securities laws, Holder shall
not assign, encumber or dispose of any interest in the Shares except in compliance with the provisions below and applicable securities
laws.

 

(a)           Right
of First Refusal on Vested Shares. Before any Vested Shares held by Holder or held by any transferee of Holder (either
being sometimes referred to herein as the “Holder”) may be sold or otherwise transferred (including
transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first refusal to purchase such
Vested Shares on the terms and conditions set forth in this Section 9(a) (the “Right of First Refusal”).

 

(i)            Notice
of Proposed Transfer. The Holder of the Vested Shares shall deliver to the Company a written notice (the “Notice”)
stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such Vested Shares (the “Offered
Shares”); (ii) the name of each proposed purchaser or other transferee (“Proposed Transferee”);
(iii) the number of Vested Shares to be transferred to each Proposed Transferee; and (iv) the terms and conditions of
each proposed sale or transfer. The Holder shall offer the Offered Shares at the same price (the “Offered Price”)
and upon the same terms (or terms as similar as reasonably possible) to the Company or its assignee(s).

 

(ii)           Exercise
of Right of First Refusal. At any time within 30 days after receipt of the Notice,
the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than
all, of the Offered Shares proposed to be transferred to any one or more of the Proposed Transferees, at the purchase price determined
in accordance with subsection (iii) below.

 

(iii)         Purchase
Price. The purchase price (“Purchase Price”) for the Offered Shares purchased by the Company
or its assignee(s) under this Section 9(a) shall be the Offered Price. If the Offered Price includes consideration
other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Committee.

 

(iv)          Payment.
Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation
of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee,
to the assignee), or by any combination thereof within 30 days after receipt of the Notice or in the manner and at the times set
forth in the Notice.

 

    5

     

    

 

(v)            Holder’s
Right to Transfer. If all of the Offered Shares proposed in the Notice to be transferred to a given Proposed Transferee
are not purchased by the Company and/or its assignee(s) as provided in this Section 9(a), then the Holder may sell or
otherwise transfer such Offered Shares to that Proposed Transferee at the Offered Price or at a higher price, provided that such
sale or other transfer is consummated within 60 days after the date of the Notice and provided further that any such sale or other
transfer is effected in accordance with any applicable securities laws and the Proposed Transferee agrees in writing that the
provisions of this Section 9 shall continue to apply to the Offered Shares in the hands of such Proposed Transferee. If the
Offered Shares described in the Notice are not transferred to the Proposed Transferee within such period, or if the Holder proposes
to change the price or other terms to make them more favorable to the Proposed Transferee, a new Notice shall be given to the
Company, and the Company and/or its assignees shall again be offered the Right of First Refusal before any Offered Shares held
by the Holder may be sold or otherwise transferred.

 

(vi)          Exception
for Certain Family Transfers. Anything to the contrary contained in this Section 9(a) notwithstanding, the transfer
of any or all of the Vested Shares during Holder’s lifetime or on Holder’s death by will or intestacy to Holder’s
Immediate Family (as defined below) or a trust for the benefit of Holder’s Immediate Family shall be exempt from the provisions
of this Section 9(a). “Immediate Family” as used herein shall mean spouse, lineal descendant or
antecedent, father, mother, brother or sister. In such case, the transferee or other recipient shall receive and hold the Shares
so transferred subject to the provisions of this Section, and there shall be no further transfer of such Shares except in accordance
with the terms of this Section 9.

 

(b)             Company’s
Right to Purchase upon Involuntary Transfer. In the event, at any time after the
date of this Agreement, of any transfer by operation of law or other involuntary transfer (including divorce or death, but excluding,
in the event of death, a transfer to Immediate Family as set forth in Section 9(a)(vi) above) of all or a portion of
the Shares by the record holder thereof, the Company shall have the right to purchase all of the Shares transferred at the greater
of the purchase price paid by Holder pursuant to this Agreement or the Fair Market Value (as defined in the Plan) of the Shares
on the date of transfer. Upon such a transfer, the person acquiring the Shares shall promptly notify the Secretary of the Company
of such transfer. The right to purchase such Shares shall be provided to the Company for a period of 90 days following receipt
by the Company of written notice by the person acquiring the Shares.

 

(c)             Assignment.
The right of the Company to purchase any part of the Shares may be assigned in whole or in part to any stockholder or stockholders
of the Company or other persons or organizations.

 

(d)             Restrictions
Binding on Transferees. All transferees of Shares or any interest therein will receive and hold such Shares or interest
subject to the provisions of this Agreement. Any sale or transfer of the Shares shall be void unless the provisions of this Agreement
are satisfied.

 

(e)             Termination
of Rights. The Right of First Refusal and the Company’s right to repurchase the Shares in the event of an involuntary
transfer pursuant to Section 9(b) above shall terminate upon the first sale of Common Stock of the Company to the general
public pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission under
the Securities Act of 1933, as amended (the “Securities Act”).

 

    6

     

    

 

(f)              No
Transfer of Unvested Shares. Unvested Shares may not be sold or otherwise transferred by Holder, and Holder may not grant
a lien or security interest in, or pledge, hypothecate or encumber any Unvested Shares, without the Company’s prior written
consent.

 

10.          Restrictive
Legends and Stop-Transfer Orders.

 

(a)             Legends.
Holder understands and agrees that the Company will cause the legends set forth below or legends substantially equivalent thereto,
to be placed upon any certificate(s) evidencing ownership of the Shares, together with any other legends that may be required
by state or federal securities laws, or by the Bylaws of the Company, or by any other agreement between Holder and the Company
or between Holder and any third party:

 

THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES
LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED
OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.
INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD
OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER
TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

THE SHARES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON PUBLIC RESALE, TRANSFER AND A RIGHT OF REPURCHASE AND RIGHT OF FIRST REFUSAL
OPTION HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN A RESTRICTED STOCK PURCHASE AGREEMENT BETWEEN THE ISSUER AND
THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH PUBLIC SALE
AND TRANSFER RESTRICTIONS AND THE RIGHTS OF REPURCHASE AND FIRST REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES.

 

(b)             Stop-Transfer
Instructions. Holder agrees that, in order to ensure compliance with the restrictions referred to herein, the Company
may issue appropriate “stop-transfer” instructions to its transfer agent, if any, and that, if the Company transfers
its own securities, it may make appropriate notations to the same effect in its own records.

 

(c)             Refusal
to Transfer. The Company will not be required (i) to transfer on its books any Shares that have been sold or otherwise
transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of such Shares or to accord
the right to vote or pay dividends to any Holder or other transferee to whom such Shares have been so transferred.

 

    7

     

    

 

(d)             Market
Standoff Agreement. Holder agrees in connection with any registration of the Company’s securities that, upon the
request of the Company or the underwriters managing any public offering of the Company’s securities, Holder will not to
sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company
(other than those included in the registration) without the prior written consent of the Company or such underwriters, as the
case may be, for such period of time after the effective date of such registration and subject to all restrictions as the Company
or the underwriters may specify for employee-shareholders generally. Holder agrees to execute an agreement reflecting the foregoing
as may be requested by the underwriters at the time of the Company’s public offering. Holder further agrees that the Company
may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period.

 

11.          Compliance
with Laws and Regulations. The issuance and transfer of the Shares hereunder will be subject to and conditioned upon compliance
by the Company and Holder with all applicable state and federal laws and regulations and with all applicable requirements of any
stock exchange on which the Company's Common Stock may be listed at the time of such issuance and transfer.

 

12.          Ancillary
Agreements.

 

(a)             Voting
Agreement. As a condition to purchase of the Shares, and concurrently with the purchase
of the Shares, Holder hereby agrees that Holder shall be deemed to be a “Common Holder” under, and shall be bound
by the provisions of, the Amended and Restated Voting Agreement dated December 3, 2020 by and among the Company and certain
equityholders of the Company party thereto, as such agreement may be amended, modified or superseded from time to time (the “Voting
Agreement”), including without limitation the drag-along provisions under such agreement. Holder also agrees to
execute a counterpart signature page to the Voting Agreement concurrently with the execution of this Agreement or at any
other time if requested. A copy of the Voting Agreement is available from the Company.

 

13.          Miscellaneous.

 

(a)             Governing
Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto
shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles
of conflicts of law.

 

(b)             Entire
Agreement; Enforcement of Rights. This Agreement (including the Plan) sets forth the entire agreement and understanding
of the parties relating to the subject matter herein and merges all prior discussions between them. No modification of or amendment
to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties
to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of
any rights of such party.

 

    8

     

    

 

(c)             Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate
such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for
such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of the Agreement shall
be interpreted as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable in accordance
with its terms.

 

(d)             Construction.
This Agreement is the result of negotiations between and has been reviewed by each of the parties hereto and their respective
counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity
shall be construed in favor of or against any one of the parties hereto.

 

(e)             Notices.
Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient when delivered personally
or sent by telegram or fax or 48 hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid,
and addressed to the party to be notified at such party’s address as set forth below or as subsequently modified by written
notice.

 

(f)              Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together
shall constitute one instrument.

 

(g)             Successors
and Assigns. The rights and benefits of this Agreement shall inure to the benefit of, and be enforceable by the Company’s
successors and assigns. The rights and obligations of Holder under this Agreement may only be assigned with the prior written
consent of the Company.

 

(h)             Further
Instruments. The parties agree to execute such further instruments and to take such further action as may be reasonably
necessary to carry out the purposes and intent of this Agreement.

 

(i)              No
Obligation to Continue Employment or Consultancy. Nothing in this Agreement will confer or be deemed to confer on Holder
any right to continue in the employ of, or to continue any other relationship with, the Company, be deemed to modify Holder’s
 “at-will” status with the Company, or limit in any way the right of the Company to terminate Holder’s employment
or other relationship at any time, with or without cause.

 

(j)              Incorporation
of Plan. This Agreement is subject to all the provisions of the Plan, the provisions of which are hereby made a part of
this Agreement, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time
be promulgated and adopted by the Committee pursuant to the Plan. In the event of any conflict between the provisions of this Agreement
and those of the Plan, the provisions of the Plan shall control unless expressly provided in the Plan.

 

[Signature page follows.]

 

    9

     

    

 

IN
WITNESS OF THE FOREGOING, the parties have executed this Agreement effective as of the date first set forth above.

 

		COMPANY:
	 
		EDGEWISE THERAPEUTICS, INC.
	 
		By:	
	 		Name:
	 		Title:

 

HOLDER ACKNOWLEDGES
AND AGREES THAT THE VESTING OF ANY SHARES ISSUED PURSUANT TO THIS AGREEMENT IS EARNED ONLY BY CONTINUING EMPLOYMENT OR CONSULTANCY
AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER). HOLDER
FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE PLAN, WHICH IS INCORPORATED HEREIN BY REFERENCE, SHALL
CONFER UPON HOLDER ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT OR CONSULTANCY BY THE COMPANY, NOR SHALL IT INTERFERE IN
ANY WAY WITH HOLDER’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE HOLDER’S EMPLOYMENT OR CONSULTANCY AT ANY TIME,
WITH OR WITHOUT CAUSE.

 

Holder acknowledges
receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby enters
into this Agreement subject to all of the terms and provisions thereof. Holder has reviewed the Plan and this Agreement in their
entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions
of the Agreement. Holder hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee
upon any questions arising under the Plan or this Agreement.

 

	Dated:	 	 	  	 
	 	 	Name:	 

 

Signature page to Edgewise Therapeutics, Inc.

Restricted Stock Purchase Agreement

 

     

     

    

 

EXHIBIT A

 

Stock Power and Assignment

Separate from Certificate

 

FOR VALUE RECEIVED
and pursuant to that certain Restricted Stock Purchase Agreement dated as of _________________, 20__, the undersigned hereby sells,
assigns and transfers unto Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”),
________ shares of the Company’s Common Stock standing in the undersigned’s name on the books of the Company represented
by Certificate No. __________ delivered herewith, and does hereby irrevocably constitute the Secretary of the Company as attorney-in-fact,
with full power of substitution, to transfer said stock on the books of the Company.

 

Dated: _________________

 

	 
	 	Name:	 
	 
	 	(Spouse’s Signature, if any)	 
	 
	 	(Please Print Name)	 

 

Instruction:
Please do not fill in any blanks other than the blanks for your name and signature. Please sign exactly as you would like your
name to appear on the issued stock certificate. The purpose of this assignment is to enable the Company to exercise its rights
set forth in the Restricted Stock Purchase Agreement without requiring additional signatures on your part.

 

    1

     

    

 

EXHIBIT B

 

Section 83(b) Election

 

The undersigned Taxpayer hereby elects,
pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in gross income as compensation
for services the excess (if any) of the fair market value of the shares described below over the amount paid for those shares.

 

		1.	The name, taxpayer identification number, address of the undersigned, and the taxable year for
which this election is being made are:

 

TAXPAYER’S NAME: _____________________________________________

 

TAXPAYER’S ADDRESS: _____________________________________________

 

TAXPAYER’S SOCIAL
SECURITY NUMBER: ____________________________  

 

TAXABLE YEAR: Calendar
Year 20__

 

		2.	The property which is the subject of this election is ________ shares of common stock of Edgewise Therapeutics, Inc.
(the “Company”).

 

		3.	The property was transferred to the undersigned on ________.

 

		4.	The shares are subject to the following restrictions: The Company may repurchase all or a portion
of the shares at the Taxpayer’s original purchase price under certain conditions at the time of Taxpayer’s termination
of employment or services.

 

		5.	The fair market value of the property at the time of transfer (determined without regard to any
restriction other than a nonlapse restriction as defined in Section 1.83-3(h) of the Income Tax Regulations) is $______
per share x ____________ shares = $ __________.

 

		6.	For the property transferred, the undersigned paid $_____ per share x __________ shares = $ _____________.

 

		7.	The amount to include in gross income is $ ______________. [The result of the amount reported
in Item 5 minus the amount reported in Item 6.].

 

The undersigned taxpayer will file this
election with the Internal Revenue Service office with which taxpayer files his or her annual income tax return not later than
30 days after the date of transfer of the property. A copy of the election also will be furnished to the person for whom the services
were performed. Additionally, the undersigned will include a copy of the election with his or her income tax return for the taxable
year in which the property was transferred. The undersigned is the person performing the services in connection with which the
property was transferred.

 

Dated: ______________, 20___

	 	 
	 	Taxpayer’s SignatureExhibit 10.5

 

 

 

March 3, 2021

 

Kevin Koch, Ph.D. 

c/o Edgewise Therapeutics, Inc.

 

Re: Confirmatory Employment Letter

 

Dear Dr. Koch:

 

This confirmatory
employment letter agreement (the “Agreement”) is entered into between you and Edgewise Therapeutics, Inc.
(the “Company” or “we”), effective as of the effective date of the Company’s registration
statement relating to the Company’s initial public offering (the “Effective Date”), to confirm the terms
and conditions of your employment with the Company as of the Effective Date.

 

1.            Title;
Position. You will continue to serve as the Company’s President and Chief Executive Officer. You also will continue
to report to the Company’s Board of Directors (the “Board”) and will perform the duties and responsibilities
customary for such position and such other related duties as are reasonably assigned by the Company’s Board.

 

2.            Location.
You will perform your duties from the Company’s corporate offices located in Boulder, Colorado (with the exception of the
period during which any shelter-in-place order, quarantine order, or similar work-from-home requirement affecting your ability
to work at the Company’s corporate offices remains in effect), subject to customary travel as reasonably required by the
Company and necessary to perform your job duties.

 

3.            Base
Salary. Your annual base salary is currently $442,000, but will be increased to $550,000 effective upon the Effective Date
(“Salary”), which will be payable, less any applicable withholdings, in accordance with the Company’s
normal payroll practices. Your Salary will be subject to review and adjustment from time to time by our Board or its Compensation
Committee (the “Committee”), as applicable, in its sole discretion.

 

4.            Annual
Bonus. Your current target fiscal year annual cash bonus target is 40%, but will be increased to 50% upon the Effective Date,
of your annual base salary earned during the fiscal year, based on achieving performance objectives established by the Board or
the Committee, as applicable, in its sole discretion and payable upon achievement of those objectives as determined by the Committee.
Unless determined otherwise by the Board or Committee, as applicable, (i) any such bonus will be subject to your continued
employment through and until the date of payment and (ii) any bonus for the fiscal year in which you commence employment
with the Company will be prorated based on the period during such fiscal year that you are employed with the Company. Any such
bonus amounts paid will be subject to any applicable withholdings. Your annual bonus opportunity and the applicable terms and
conditions may be adjusted from time to time by our Board or the Committee, as applicable, in its sole discretion.

 

    

     

    

 

5.            Equity
Awards. You will be eligible to receive awards of stock options or other equity awards pursuant to any plans or arrangements
the Company may have in effect from time to time. The Board or Committee, as applicable, will determine in its sole discretion
whether you will be granted any such equity awards and the terms of any such award in accordance with the terms of any applicable
plan or arrangement that may be in effect from time to time.

 

6.            Employee
Benefits. You will continue to be eligible to participate in the benefit plans and programs established by the Company for
its employees from time to time, subject to their applicable terms and conditions, including without limitation any eligibility
requirements. The Company will reimburse you for reasonable travel or other expenses incurred by you in the furtherance of or
in connection with the performance of your duties under this Agreement, pursuant to the terms of the Company’s expense reimbursement
policy as may be in effect from time to time. The Company reserves the right to modify, amend, suspend or terminate the benefit
plans, programs, and arrangements it offers to its employees at any time.

 

7.            Severance.
You will be eligible for the Company’s Executive Change in Control and Severance Plan (the “Severance Plan”).
Your Participation Agreement under the Severance Plan will specify the severance payments and benefits you could be eligible to
receive in connection with certain terminations of your employment with the Company. These protections will supersede all other
severance payments and benefits you would otherwise currently be eligible for, or would become eligible for in the future, under
any plan, program or policy that the Company may have in effect from time to time.

 

8.            Confidentiality
Agreement. As an employee of the Company, you will continue to have access to certain confidential information of the Company
and you may, during the course of your employment, develop certain information or inventions that will be the property of the
Company. To protect the interests of the Company, your acceptance of this Agreement confirms that the terms of the Company’s
Confidential Information and Invention Assignment Agreement November 17, 2017 entered into between you and the Company (the
 “Confidentiality Agreement”) still apply.

 

9.            At-Will
Employment. This Agreement does not imply any right to your continued employment for any period with the Company or any parent,
subsidiary, or affiliate of the Company. Your employment with the Company is and will continue to be at-will, as defined under
applicable law. This Agreement and any provisions under it will not interfere with or limit in any way your or the Company’s
right to terminate your employment relationship with the Company at any time, with or without cause, to the extent permitted by
applicable laws.

 

10.          Protected
Activity Not Prohibited. The Company and you acknowledge and agree that nothing in this Agreement limits or prohibits you
from filing and/or pursuing a charge or complaint with, or otherwise communicating or cooperating with or participating in any
investigation or proceeding that may be conducted by, any federal, state or local government agency or commission, including the
Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration,
and the National Labor Relations Board (“Government Agencies”), including disclosing documents or other information
as permitted by law, without giving notice to, or receiving authorization from, the Company. In addition, nothing in this Agreement
is intended to limit employees’ rights to discuss the terms, wages, and working conditions of their employment, nor to deny
employees the right to disclose information pertaining to sexual harassment or any unlawful or potentially unlawful conduct, as
protected by applicable law. You further understand that you are not permitted to disclose the Company’s attorney-client
privileged communications or attorney work product. In addition, you acknowledge that the Company has provided you with notice
in compliance with the Defend Trade Secrets Act of 2016 regarding immunity from liability for limited disclosures of trade secrets.
The full text of the notice is attached in Appendix A.

 

    -2-

     

    

 

11.          Miscellaneous.
This Agreement, together with the Confidentiality Agreement, the Severance Agreement and the stock options granted to you by the
Company under its 2017 Equity Incentive Plan and the applicable award agreements thereunder, constitute the entire agreement
between you and the Company regarding the material terms and conditions of your employment, and they supersede and replace all
prior negotiations, representations or agreements between you and the Company. This Agreement will be governed by the laws of
the State of Colorado but without regard to the conflict of law provision. This Agreement may be modified only by a written agreement
signed by a duly authorized officer of the Company (other than yourself) and you.

 

[Signature page follows]

 

    -3-

     

    

 

To confirm the current terms and conditions
of your employment, please sign and date in the spaces indicated and return this Agreement to the undersigned.

 

	 	Sincerely,
	 	 
	 	EDGEWISE
    THERAPEUTICS, INC.
	 	 
	 	 
	 	By:	/s/
    Peter A. Thompson, MD
	 	 	Name: Peter A.
    Thompson, MD
	 	 	Title: Chairman and Co-Founder
	 	 
	 	Date: 	March 4,
    2021

 

 

Agreed to and accepted:

 

 

	/s/
    Kevin Koch 	 
	Kevin
    Koch	 
	 	 
	Date:
    	March 5,
    2021	 

 

    -4-

     

    

 

Appendix A

 

Section 7 of the Defend Trade Secrets
Act of 2016

 

“ . . . An individual shall not
be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that—(A) is
made—(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney;
and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint
or other document filed in a lawsuit or other proceeding, if such filing is made under seal. . . . An individual who files a lawsuit
for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the
individual and use the trade secret information in the court proceeding, if the individual—(A) files any document containing
the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.”

 

    -5-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]